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1. Introduction  
 
Evident variability among patients concerning pharmacokinetics and pharmacodynamics of the 
most often prescribed drugs in clinical practice is one of the major challenges nowadays (Ma and 
Lu 2011, Preissner, Hoffmann et al. 2013). Besides intrinsic (age, gender, weight, height, disease,  
organ impairment, ethnicity, race) and extrinsic factors that summarize information associated 
with the patient environment (use of other drugs,  tobacco, alcohol, and food habits), this 
variability is also influenced by inherited polymorphism of genes that have an important impact 
on drug detoxifying enzymes, drug transporters and drug targets (Kantae, Krekels et al. 2017).  
To date, a number of genetic variants of drug metabolizing enzymes, drug transporters, receptors, 
and different modulators (like nuclear receptors genes) have been discovered (Kim, Cheong et al. 
2014). Hence, the presence of genetic aberrations regarding expression, regulation and activity of 
genes coding for Phase I and Phase II enzymes, membrane transport proteins and drug targets, 
may be a useful tool for understanding as well as predicting drug efficacy and/or toxicity related 
to drug use (Krasniqi, Dimovski et al. 2016; Maagdenberg, Vijverberg et al. 2016). This study, 
for the first time explored frequency and distribution of the most important variant alleles of drug 
metabolizing enzymes and drug target in Kosovo.  This data is missing in the case of Kosovo‟s 
population. Kosovo is located in the heart of Balkan Peninsula. According to the 2011 census, 
Kosovo‟s population is 1,739,825, excluding the northern part of the country. 92.9% of Kosovo‟s 
inhabitants are ethnic Albanians. The rest includes minorities of Caucasian origin (Serbs 1.5%, 
Bosniaks 1.6%, and Gorani 0.6%) as well as of Asian origin (Turks 1.1% and Romani 0.5%) 
(Link 1) Characterization of the European Y-chromosome DNA haplogroups showed that in 
Kosovo‟s population there are present haplogroups that are characteristic for South-eastern and 
Western Europe. In addition, this data also proves different human migrations carrying mainly 
Neolithic and Bronze Age European ancestry (Link 2).  
Polymorphic detoxifying enzymes of phase I metabolize nearly 59% of drugs cited in studies dealing with 
adverse drug reactions (ADR). Among these Phase I enzymes, CYPs constitute 75-86%. On the other 
hand, only 20% of drugs that are substrates of non-polymorphic enzymes have been part of ADR reports.  
These findings suggest that genetic variability in drug detoxifying enzymes is likely to be an 
important factor contributing to the incidence of ADRs. A number of published studies have 
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pointed out the importance of pharmacogenomics in decreasing and/or preventing ADRs 
(Phillips, K. A. et al 2001).  
Besides, genomic data has become important in the assessment of the efficacy and safety of a 
medicinal product in the course of its regulatory approval. 
Information on genomic markers is increasingly included in product information. By including 
pharmacogenomics information into the SPC (eng. Summary of Product Characteristics -SmPCs), 
regulatory authorities wish to point out the importance of the role of genomic variability in 
pharmacotherapy. Likewise, information regarding the category that the pharmacogenetics 
information belongs to, is also being included, i.e. whether testing is mandatory, recommended, 
or of an informational nature. 
Drug‟s regulatory agencies, such as the European Medicines Agency (EMA) and the Food and 
Drug Administration (FDA) in the US proposed these genetic variants (polymorphisms) as 
biomarkers for therapeutic guidance or safety warnings (Ehmann F et al 2015).  
The link between pharmacogenomics and pharmacovigilance also plays an important role in 
monitoring the incidence of side effects in the post-marketing period. 
At this point, the European Medicine Agency policy is oriented towards the implementation of  
pharmacogenetics findings in drug development, especially in pharmacokinetic characterization 
of drugs as a key step in designing and performing drug development, as well as in conducting 
drug evaluation studies (Ehmann, Caneva et al. 2014). Several medical products that have been 
authorized by the EMA in their product information SmPC contain pharmacogenetics (PGx) 
information (Link 3). Out of the total number, 15% of such products contain pharmacogenetics 
data in SmPC that have a direct impact in patient‟s treatment, showing that pharmacogenetics 
nowadays has become an essential part in the development and post-marketing phase  for 
numerous of drugs. PGx also has a significant role in the management of drug‟s benefits and risks 
in clinical practice (Link 4).     
In the US, out of approved drug labels from Food and Drug Administration (FDA) mentioning 
human genomic biomarkers, 62,0% contain information about the most common CYPs 
polymorphisms such as CYP2C9 (7.0%; warfarin, NSAIDs, phenytoin), CYP2C19 (17.0%; 
clopidogrel, PPIs, barbiturates, voriconazole), CYP2D6 (35.0%; tamoxifen, clozapine, 
risperidone, metoprolol, codeine etc.), as well as about gene polymorphisms of Phase II enzymes 
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such as  UGT1A1 (nilotinib, irinotecan) and drug target VKORC1 (warfarin) (Foster and Sharp 
2002). A total of 251 drugs has drug labels containing pharmacogenetic information. 
Investigation regarding the rational use of drugs as well as optimization and personalization of 
pharmacotherapy has enabled the systematic identification of human genes performed within the 
Human Genome Project (Weinshilboum 2003, Green 2016). 
In addition to revealing inter-individual differences in drug response, numerous investigations 
conducted on different ethnic groups also identified an existing association between genetic 
variants and disease susceptibility, drug metabolism and environmental response, as well as 
reported prevalence of these genetic variants in respective populations. As a result, human 
genome sequencing reinforced the interest of science in biological differences between races and 
ethnic groups (Mersha and Abebe 2015; Kaplun, Hogan et al. 2016). 
Data generated from genome resequencing studies has shown that the majority of genetic 
variability in human population is attributed more to intra-population differences rather than 
interethnic differences (Garcia-Martin 2008, Stranger, Stahl et al. 2011). 
A recently published study examined worldwide patterns of genetic diversity and signals of 
natural selection for ADME (drug absorption, distribution, metabolism and excretion) human 
genes. This study comprised 283 drug metabolizing enzymes (DMEs) in 62 different ethnic 
groups. The study‟s findings suggest that genetic variants concerning pharmacokinetic parameters 
such as drug absorption, distribution, metabolism and excretion could have an impact on the 
intra-population heterogeneity in drug response (Li, Zhang et al. 2011).  
In clinical terms, genetic variants of Phase I enzymes CYP2C9, CYP2C19, and CYP3A5, as well 
as drug target VKORC1, are among the most important. Their function - catalytic activity and 
prevalence of variant alleles in European populations have been studied intensively. Given the 
paucity of data on genetic variants of these enzymes and drug target in Kosovo, in this study, we 
aimed to assess for the first time frequency distribution of these gene variants in Kosovo‟s 
population.   
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1.1. Cytochrome P450 (CYP450) enzyme system 
 
The human cytochrome P450 (CYP) superfamily comprises a large and diverse group of enzymes  
(Guengerich FP, 2008).  In humans, out of 115 CYP genes, 57 genes are active and the rest are 
pseudogenes (Sim, S. C. et al 2010). Most of the CYPs are found in the liver but certain amounts 
are also found in other parts of the body, such as intestines, lung, and kidney (Bozina N et al. 
2009). Liver CYPs are composed of three main families of enzymes named CYP1, CYP2 and 
CYP3. In addition, within CYPs there is also the CYP4 family, whose major activity is its 
contribution in detoxification of eicosanoids, fatty acids and of a small number of xenobiotics 
(Simpson, 1997; Honkakoski, P. and M. Negishi 2000). CYP enzymes catalyze biotransformation 
of drugs, environmental xenobiotics, toxins, prostaglandins, fatty acids, steroidal hormones and 
lipids within Phase I of metabolism (Gueguen, Mouzat et al. 2006; Pandey and Fluck 2013). 
Within 57 active genes in humans that encode important detoxifying enzymes, the CYP1A2, 
CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 metabolize about 90 %of drugs including 
clopidogrel, warfarin, NSAIDs, phenytoin, tacrolimus, tamoxifen, codeine, PPIs, barbiturates, 
and others (Lynch T et al. 2007; Zhou et al, 2009). CYPs also play an important role in the 
metabolism of the arachidonic acid. CYP1A2, CYP2C, and CYP2J2 metabolize the arachidonic 
acid into epoxyeicosatrienoic acids (EETs) which possess anti-inflammatory, vasodilating, anti-
thrombotic, anti-apoptotic, natriuretic, as well as cardioprotective effects (Zordoky and El-Kadi 
2010). The two main characteristics of CYPs‟ function include drug metabolism and 
bioactivation. They are involved mainly in the oxidation reactions serving as a monooxygenases, 
peroxydases and oxydases but can also serve as catalysts in reduction reactions. They account for 
approximately 75% of the total number of different metabolic reactions (Johansson I, 2011). A 
number of xenobiotics undergo detoxification processes or activation into reactive intermediate 
substances (Thier R et al, 2003). CYPs play a significant role in the duration and intensity of 
drug‟s action, detoxification of xenobiotics as well as in their transformation into toxic 
substances, mutagens and carcinogens (Nebert DW, 2001; Wogan et al. 2004). The inter-
individual difference concerning the amount and activity of CYP450 enzymes, is due to the 
genetic and environmental factors. The genetic factors that contribute to inter-individual 
variability of CYPs‟ activity are variant alleles with changed/impaired function comparing to 
“wild type” gene. Substitution in the aminoacid sequence of protein may increase or rather 
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decrease enzyme activity. Other factors that may have an influence in gene transcription and, 
subsequently, in the quantity of CYP detoxifying enzymes are drugs (rifampin, barbiturate), fruits 
(grapefruit, orange, cranberry, apple, mango), vegetables (cruciferous vegetables such as 
cabbage, watercress and broccoli as well as spinach, red pepper, tomato and carrot), herbal 
medicines (chamomile, gingko), habits (alcohol, smoking) and diseases (diabetes, 
hypothyroidism and hyperthyroidism) (Fujita K, 2004; Nahrstedt A et al, 2010; Hermann R et al 
2012). 
Increased enzyme activity may be consequence of gene duplications, which generates an 
overexpression of CYP enzymes (Haouala et al., 2011; Sadee W et al 2011). On the other hand, a 
reduced activity of CYPs may be due to mutations in genes coding for these enzymes, which 
blocks enzyme‟s synthesis, or produce inactive enzymes (Ingelman-Sundberg, M. 2004). In 
addition, CYPs decreased activity may result from the exposure to environmental factors such as 
xenobiotics or infectious diseases, which suppress CYP450 expression, or as a consequence of 
suppression or inactivation of the existing enzymes by these factors. In addition to various disease 
conditions (chronic hepatitis C, steatosis, alcoholic liver diseases  and others), liver‟s CYPs‟ 
expression is also under the control of nuclear receptors. The CYP1 gene family is regulated by 
AhR (aryl hydrocarbon receptor), the CYP2 family is regulated by CAR (constitutive androstane 
receptor), the CYP3 family is regulated by PXR (pregnane X receptor), and PPARα (peroxisome 
proliferator-activated receptors) regulates the CYP4 family (Aleksunes and Klaassen 2012). 
Many drugs affect CYPs‟ activity causing clinically significant changes in the concentrations of 
co-administered drugs. This impact of some drugs on the activity of CYPs, known as 
pharmacokinetic drug–drug interactions, produces adverse effects that in some cases can be life 
threatening. Some of these drugs that influence CYP enzymes induce the ability of the specific 
pathway to metabolize drugs, whereas others inhibit it. With respect to CYPs induction, it may 
occur through five mechanisms (Fuhr, U.  2000). The CYP2E1 enzyme is selectively induced by 
ethanol primarily by mediating enzyme stabilization. The other mechanisms are likely mediated 
by intracellular receptors such as the peroxisome proliferator activated receptor (PPAR), aryl 
hydrocarbon (Ah) receptor, pregnane X receptor (PXR, rifampicin induction) and the constitutive 
androstane receptor (CAR, phenobarbital induction) (Fuhr 2000, Prakash, Zuniga et al. 2015). 
The Ah receptor belongs to the basic-helix-loop-helix-PAS (bHLH-PAS) family and is a 
transcription factor while the other receptors such as CAR, PXR, and PPAR belong to the ligand-
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activated orphan nuclear receptors (Waxman 1999, Gonzalez 2008). Induction by drugs produces 
stimulation of the other drug metabolism and consequently increases or reduces its therapeutic 
effect (Zhou SF et al 2009). 
CYPs inhibition can be reversible or irreversible. Irreversible inhibition is likely the more 
common mechanism. On a kinetic basis, reversible inhibition can be divided into competitive, 
noncompetitive, and uncompetitive inhibition. Competitive inhibition is a type of inhibition 
where both the inhibitor and the substrate (drug) compete for the same binding site within a 
specific CYP enzyme. On the other side, in noncompetitive inhibition, the inhibitor and the 
substrate bind in different sites of the same enzyme whereas in uncompetitive inhibition, 
inhibitory substance binds exclusively to a CYP enzyme that forms a single complex with the 
drug-substrate (Ito, Iwatsubo et al. 1998). According to some studies, CYPs‟ reversible inhibitors 
comprise drugs such as miconazole (CYP2C9), fluoxetine (CYP2D6), ciprofloxacin (CYP1A2) 
and itraconazole (CYP3A4) (O'Reilly, Goulart et al. 1992, Sager, Lutz et al. 2014, Dirix, 
Swaisland et al. 2016, Meyer, Proctor et al. 2016). Inhibition of CYPs activity by a specific drug 
will generate deterioration of the other drug metabolism, producing an increased or toxic effect of 
that drug. Therefore, CYPs‟ inhibition results in a genetically decreased expression of these 
enzymes (Sideras, 2010). 
In the case of CYPs‟ induction or inhibition, the main inhibitors of CYP2C9 are fluconazole, 
amiodarone, isoniazid, valproic acid, fenofibrate, and sertraline, while the main inducers are 
barbiturates, carbamazepine, and rifampin. As far as CYP2C19 is concerned, its most important 
inhibitors are omeprazole, chloramphenicol, cimetidine, fluoxetine, and oxcarbamazepine, while 
carbamazepine, rifampicin, pentobarbital, prednisone, and norethindrone are its main inducers 
(Zhou SF et al. 2010). Finally, CYP3A5‟s major inhibitors are chlorpheniramine, cocaine, 
diltiazem, indinavir, lovastatin, while the most important inducers are drugs such as 
carbamazepine, efavirenz and glucocorticoids (Liu, Y. T., 2007).   
 
1.2. Genetic variants of drug target VKORC1  
 
VKORC1 (Vitamin K 2,3-epoxide reductase complex subunit 1) protein is the drug target of 
coumarin anticoagulants like warfarin and is encoded by VKORC1 gene. Its function to convert 
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vitamin K epoxide into vitamin K is an essential step in the Vitamin K cycle. Genetic variants of 
VKORC1 are responsible for partial or total warfarin resistance (Watzka, M. et al 2011). Thus, 
information regarding the presence of VKORC1 genetic variant enables to determine the starting 
dose of warfarin and avoid of drugs‟ side effects (Buzoianu, Trifa et al. 2012). 
 
1.3. CYP450 phenotypes  
 
The presence of different variant alleles and metabolism intensity determine most often three 
categories of phenotypes and in some cases, such as CYP2C19 and CYP2D6 four phenotypes. 
First, a poor metabolizer (PMs) lacks both active alleles and is characterized by a decreased (or 
absence of) enzyme activity and, consequently, accumulation of different drug-substrates. This 
phenotype is an example of the autosomal recessive inheritance. The extensive metabolizer (EM) 
possesses two functional alleles and manifest expressed metabolism. This phenotype (EM) is 
present in the majority of population. In addition to EMs, the ultra-extensive metabolizer (UEM) 
is marked by amplification of the respective gene (carrying more than two copies of the active 
gene) and is associated with the rapid/ultrarapid detoxification of substrates. This feature is 
inherited in an autosomal dominant way. The last phenotype is the intermediate metabolizer (IM) 
which is the intermediate form of metabolizer and individuals belonging to this group carry one 
normal (wt-wild type) and one defective allele (Ingelman-Sundberg M et al 2007; Birdwell KA et 
al 2015).  The determination of drug metabolism phenotype may be conducted by either 
phenotypisation or genotypisation. 
 
1.3.1. Phenotypisation  
Phenotypisation is accomplished by administration of a test drug whose metabolism is known to 
be strongly linked to the activity of a certain drug metabolizing enzyme and followed by 
calculation of the metabolic ratio (MR), which represents the ratio between the pattern drug 
(unchanged drug) and its metabolite measurement in serum or urine (Zanger UM et al 2004).  The 
phenotyping process can be performed using high performance liquid chromatography (HPLC), 
liquid chromatography-mass spectrometry (LC-MS) or gas chromatography-mass spectrometry 
(GC-MS) (Tanaka E et al 2003; Trojan A et al 2012).  An advantage of phenotyping in 
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comparison with genotyping is that phenotyping reveals drug-drug interactions or any other 
defect concerning drug metabolism in general. On the other hand, phenotyping‟s disadvantages 
include the complex protocol of drug testing, unreliability of results because of the disease 
impact, with particular emphasis on liver and kidney disease, as well as possible interaction with 
other substrates (Rost KL et al 1995; Swanson JR et al 1997).  Table 1 lists some of the test drugs  
 used in determining metabolic phenotype of the most important CYP450 detoxifying enzymes.  
 
 
 
 
 
 
 
 
 
 
 
 
1.4. Genotyping  
 
Genotyping comprises the procedure of identification of CYP450 gene variants using diagnostic 
molecular methods such as polymerase chain reaction (PCR) or real-time polymerase chain 
reaction (RT-PCR). This procedure makes possible the identification of subjects that are carriers 
of two (homozygous for variant allele) or one (heterozygous for variant allele) variant allele and 
is manifested in a specific metabolic phenotype (Zhou SF, 2009a). These specific gene variants 
result in overexpression (subjects with more than two functional alleles), absence of certain active 
enzyme (subject that lack both active – wt- alleles) or generation of a defective protein that is 
characterized by a low catalytic activity (inactivating allele) (Garte S et Crosti F, 1999).  
Table 1. Test drugs for CYP450 phenotyping 
  Enzyme                                Test drug for phenotyping 
 
CYP 2C8         bisphosphonates, ibuprofen, mycophenolic acid, pioglitazone  
 
CYP 2C9         warfarin, ibuprofen, phenytoin, cyclophosphamide  
 
CYP 2C19       clopidogrel, omeprazole, amitriptyline, mephenytoin, citalopram   
 
CYP 2D6         risperidone, tamoxifen, dextromethorphan,  metoprolol, debrisoquine 
 
CYP 3A4         cyclosporine, doxorubicin, clarithromycin,  midazolam 
 
CYP 3A5         chlorpheniramine, cocaine, diltiazem, indinavir, lovastatin, methadone,  
 
CYP 1A2         caffeine, clopidogrel, theophylline, warfarin 
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Different laboratory techniques are on disposal to perform screening of these genetic variants 
linked to the altered drug metabolism.  At the beginning of genotyping, methods were based on 
multiplication of a specific segment of the gene of interest by PCR and thereafter on digestion of 
the multiplied DNA product using restriction endonucleases. Results were obtained by comparing 
the digestion product size from the amplified DNA segment to a standard molecular weight 
marker (restriction fragment length polymorphism -RFLP) (Sameer AE et al 2009, Shukla P et al 
2012). Another alternative method used in order to detect certain specific mutations located in a 
gene of interest is by an allele specific PCR where specific oligonucleotide primers for 
hybridization with common or allelic variants are employed in parallel PCR amplification 
reactions. Only oligonucleotide primers that exactly hybridize to the targeted DNA sequence 
generate amplified product (De Mare A et al 2010). 
A more advanced laboratory method used for detection of specific gene mutations is Real Time-
PCR (RT-PCR). Compared to the standard PCR, this is a more advanced molecular method used 
to multiply and detect (or quantify) simultaneously a specific region of the gene (Edwards KJ et 
al 2012; Tydén E et al 2014). This procedure corresponds to the general principles of PCR, but a 
specific feature of this method is that it monitors the progress of a PCR reaction (detection of 
amplified DNA) in real time. Real-time PCR represent the most useful machine for conducting 
quantitative nucleic acids analysis for diagnostic and research purposes (Bustin SA, 2004; Bustin 
SA, 2009). This important technique is an improvement of the original PCR established in the 
mid-1980s by the scientist Kary Mullis and his collaborators, for which he was awarded the 
Nobel Prize in Chemistry in 1993 by Royal Swedish Academy of Sciences (Peake I, 1989; 
Kubista M et al 2006). The PCR machine makes possible amplification of each nucleic acid 
sequence present in a certain sample (blood, tissue etc.) through a cyclic process that produces a 
large number of identical copies. Thereafter, these gene copies can be analyzed readily. This 
technique enabled procedures such as DNA cloning, sequencing and genetic engineering. 
However, the original PCR method as an analytical technique had significant disadvantages. The 
process of quantification of DNA sequence was extremely difficult through the use of PCR 
because this technique produced the same amount of product regardless the amount of DNA 
template used for this purpose. The development of Real-time PCR in 1992 resolved this 
handicap of PCR technique (Higuchi, R et al 1992). Real-time PCR is distinguished by the fact 
that the amount of amplified product may be monitored during the process of reaction by 
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monitoring the fluorescence of probes that proportionally corresponds to the amount of amplified 
product. In addition, the number of amplification cycles necessary for obtaining certain amount of 
amplified product is registered by the Real-time PCR machine. In contrast to the old-fashioned 
approach, Real-time PCR makes possible to calculate the efficiency of the reaction very 
precisely. Concretely, it is assumed that during each amplification cycle amplified DNA 
molecules double. Therefore, this approach allows for the calculation of the number of amplified 
DNA molecules that were present in the sample at the beginning of the process. Given the details 
of Real-time PCR mentioned above, such as detection chemistries with high efficiency as well as 
susceptible instruments and advanced assays that are available currently, the number of molecules 
of a certain DNA segment within a complex sample becomes possible to be determined with very 
high sensitivity and accuracy, enough to detect a single DNA molecule. Real-time PCR can be 
used for different purposes such as single nucleotide polymorphism (SNP) analysis, gene 
expression analysis, pathogen (bacteria or virus) detection, chromosome aberration analyses and 
detection of proteins (Kubista M et al 2006; Bustin SA et al 2009). 
Genotyping has certain advantages compared to phenotyping methods. A small quantity of blood 
or specific tissue is needed to perform genotyping and the result is not dependent on the subject‟s 
health status or drugs that the subject could use. Besides, when using the RT-PCR technique, the 
result is obtainedable in a few hours. This analysis is performed once in a lifetime, because 
genotype remains unchanged during the entire lifetime. To date, a large number of different 
variants of CYPs have been described, but this biomolecular analyses, for economic reasons, is 
conducted only for the most frequent mutations present in a population (Puehringer H et al 2010; 
Dodgen TM et al 2015).  
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a- Yasuda SU et al 2008; b- Strom CM et al 2012  c- Balram C et al 2003, d- Mirghani RA et al 2006, e- Anichavezhi D et al 2012; f- Scott SA et al 
2011, g- Gaikovitch EA et al. 2003, h-Arvanitidis K et al. 2007, i- Yan X et al, 2015   , j- Scordo MG et al 2004, k- Kapedanovska Nestorovska A et al 
2015, l- Adler G et al 2009; m- Limdi NA et al, 2008; n, Mandic D et al, 2015; 
Table 2. Table presentation of CYP2C9, CYP2C19, CYP3A5 and VKORC1 substrates, inducers, variant alleles and 
test drugs used for phenotyping 
Enzyme Enzyme substrates 
Enzyme 
inhibitors 
Enzyme 
inducers 
Most 
important 
variant 
alleles 
Test drug 
for 
phenotyping 
Allele frequency (%) 
Caucasian 
population 
 
Asian 
population 
(China) 
African 
population 
(African 
American) 
CYP2C9 diazepam, warfarin, 
NSAID-s, 
celecoxib, 
torasemide, 
cyclophosphamide, 
phenytoin,  losartan 
fluconazole, 
amiodarone, 
isoniazid, valproic 
acid, fenofibrate, 
and sertraline 
barbiturates, 
carbamazepine, 
and rifampin-
chronic 
*2 and *3 
warfarin or 
phenytoin 
 
9-16.5% 
(g, h) 
0-3% 
0.5-3.6% 
(a) 
CYP2C19 barbiturates, 
clopidogrel, 
lansoprazole, 
diazepam, 
mephenytoin, 
imipramine, 
propranolol,  
proguanil 
omeprazole, 
chloramphenicol, 
cimetidine, 
fluoxetine, and 
oxcarbamazepine 
carbamazepine, 
rifampicin, 
pentobarbital, 
prednisone, *2, *3 and 
*17 
mephenytoin 
13.07-20.02%  
(i, j, k) 
2-42% 
(e, f) 
0-19% 
(b) 
CYP3A5 sirolimus, 
tacrolimus, 
imatinib, alfentanil, 
atorvastatin, 
clarithromycin, 
codeine, 
haloperidol, 
nifedipine 
chlorpheniramine, 
cocaine, diltiazem, 
indinavir, 
lovastatin, 
methadone, 
nelfinavir, 
telithromycin, 
verapamil 
carbamazepine 
efavirenz 
glucocorticoids 
oxcarbazepine 
phenobarbital 
phenytoin 
pioglitazone 
rifabutin 
*3 midazolam 
85-95.5% 
(l) 
69-76.7% 
(c, l) 
19-27.9%,  
(d, l) 
VKORC1 Vitamin K warfarin 
acenocoumarol 
coumarin 
 -1639G>A 
1173C>T 
Lower 
warfarin 
dose 
warfarin 
TT-38% 
 
TT 
(homozygous 
for variant 
allele) 
(n) 
TT-91-93% 
(i) 
TT-0.9% 
(m) 
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1.5. Cytochrome P 450 2C9 (CYP2C9) 
 
CYP2C9 is an important subcategory within the CYP2C subfamily. Gene coding for CYP2C9 
enzyme is located on the long arm of chromosome 10, in the region that contains also genes that 
encode CYP 2C8, 2C18 and 2C19 enzymes. CYP2C9 gene is responsible for the 490 amino acids 
protein coding, weighting of 55.6 kDa (molecular weight) (Van Booven D et al 2010). To date, 
pharmacogenetic studies have revealed 67 variant alleles, but the most important of them are 
CYP2C9*1 (reference haplotype), CYP2C9*2 and CYP2C9*3 (www.cypalleles.ki.se/cyp2c9.htm, 
updated 21-Jan-2016). Each of these variant alleles is characterized by a different catalytic 
activity. CYP2C9*2 and CYP2C9*3 variants yield enzymes with reduced activity, where 
CYP2C9*3 variant allele manifest a stronger pharmacokinetic effect than CYP2C9*2. These 
alleles have been found in majority (nearly 85%) of poor metabolizers (García-Martín E et al 
2001). Depending on the capacity to metabolize substrates of CYP2C9, individuals can be 
classified as poor metabolizers (PM), intermediate (IM), or extensive (EM) (Ingelman-Sundberg 
et al 2007). Poor metabolizers in Caucasians are present with 3-5%. Enzymes coded by CYP2C9 
have a key role in the metabolism of nearly one hundred drugs, including warfarin, phenytoin, 
diazepam, valproic acid, NSAIDs (nonsteroidal anti-inflammatory drugs), celecoxib and so on. 
Likewise, these enzymes play a substantial role in the metabolism of those drugs with a narrow 
therapeutic index, such as phenytoin and warfarin (Miao L. et al. 2007). CYP2C9 catalyze nearly 
90% of phenytoin metabolism and *2 and *3 haplotypes are responsible for reduced metabolism 
of phenytoin (Van Booven, D. et al 2010). Given results of Budi et al (2015), CYP2C9*2 and 
CYP2C9*3 genotype determination could be very helpful for improving the safety of antiepileptic 
drugs such as Valproic acid (VPA) in pediatric patients and subsequently avoiding drug‟s induced 
side effects.  
CYP2C9*2 and CYP2C9*3 variants and mutations in promoter region of VKORC1 (Vitamin K 
epoxide reductase complex subunit 1) are considered to be responsible for 40-63% of the 
variability observed in warfarin dosing. Patients carrying these variants are exposed to a greater 
risk of bleeding in cases of warfarin administration and, consequently, they require lower doses 
(Kudzi, W. et al 2016).    
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 Besides phenytoin and warfarin guidelines, there are also helpful recommendations concerning 
CYP2C9 genotypes that have been issued for other medications such as celecoxib, voriconazole, 
piroxicam, flurbiprofen, and lesinurad [On FDA Biomarker List; voriconazole (VFEND) EMA 
drug label; Health Canada or Santé Canada].       
Table 3. The main substrates of CYP2C9 enzyme 
Drug class 
NSAIDs    ketoprofen, ibuprofen, diclofenac, indomethacin,   
Antidepressants fluoxetine, amitriptyline  
Angiotensin II receptor blockers (ARBs)        irbesartan, losartan 
Antidiabetic medications                               sulfonylureas (glipizide, glibenclamide), rosiglitazone  
Anticoagulants                                                                                         S-warfarin
Loop diuretics torasemide  
Antimicrobics 
Anticonvulsant 
sulfametoxazole, metronidazole 
phenytoin 
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1.6. Cytochrome P450 2C19 (CYP2C19) 
 
Polymorphism of CYP2C19 is important for pharmacotherapy with barbiturates, clopidogrel, 
lansoprazole, diazepam, mephenytoin, imipramine, propranolol, and proguanil ("Entrez Gene: 
CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19", updated on 28-Sep-2015). 
CYP2C19 activity is strongly linked with bioactivation of the prodrug clopidogrel which is an 
antiplatelet drug of choice in patients diagnosed with acute coronary syndromes (ACSs), 
especially those patients undergoing percutaneous coronary intervention (Beitelshees, A. L. et al 
2011).  
Similar to CYP2C9, CYP2C19 gene is also highly polymorphic. So far, over 30 variant alleles 
and subvariants have been identified. CYP2C19*2-*8 variants are non- function alleles that 
produce an inactive enzyme (Scott SA et al 2012; http://www.cypalleles.ki.se/cyp2c19.htm, 
updated 1-Oct-2015). The main variant alleles of CYP2C19 are *2, *3 and *17 allele. Drug 
metabolizer categories for CYP2C19 are EM, IM, PM, and ultra rapid metabolizers (UM).  
CYP2C19*2 and CYP2C19*3 alleles, account for the majority (95.0%) of the poor metabolizer 
phenotypes (McGraw J  et al 2012; Scott, S. A. et al 2012). Poor metabolizers (e.g.,*2/*2,*2/*3 
and *3/*3), in Caucasians are present with 2-5%, while 20% and 5.2% of Asians and African-
Americans respectively belong to this category. The most frequent allele in Caucasians is *2, and 
in Asians it is *3 allele (Martis S et al 2013; Fricke-Galindo I et al 2016).  
The most important nonfunctional allele of CYP2C19 is *2 allele (c.681G>A; rs4244285). 
Presence of CYP2C19*2 allele is associated with higher risk for adverse cardiovascular events in 
individuals that are heterozygous or homozygous for this allele (~25–50% of the population) (SA 
Scott et al 2011). Contrary, CYP2C19*17 allele (c.-806C>T; rs12248560;) is linked with 
increased activity as a result of enhanced gene transcription. Subjects that are homozygous for 
this variant allele (*17/*17) may be classified as ultrarapid metabolizers. Given some studies, 
there are some indications that presence of this variant allele generates increased clopidogrel 
response and platelet inhibition and likely higher risk of bleeding complications (Shuldiner, A. R. 
et al 2009). In addition, individuals carrying one defective (loss-of-function) allele and a *17 
allele represent a heterozygous genotype (e.g.,*2/*17) and a phenotypic consequences are 
presently unclear but may be an intermediate form of metabolizers between EM and IM, and 
possibly may be dependent on the substrate (Li-Wan-Po, A et al 2010). Hicks JK et al 2016, Scott 
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SA et al 2013 and Moriyama B et al 2016 published interesting and useful recommendations 
regarding the CYP2C9 genotypes that have been issued for drugs such as clopidogrel, 
amitriptyline clomipramine, doxepine, imipramine and trimipramine, sertraline, voriconazole and 
esomeprazole. 
Table 4. The main substrates of CYP2C19 enzyme 
Drug class 
  
Angiotensin II receptor  
blockers (ARBs)        
valsartan, losartan 
NSAIDs   ketoprofen, ibuprofen, diclofenac, indomethacin,   
Antidiabetics glipizide, tolbutamide 
Antiepileptics valproic acid, phenytoin, primidone, diazepam, 
phenobarbitone 
Proton pump inhibitors pantoprazole, lansoprazole, omeprazole, 
rabeprazole 
Antidepressants amitriptyline, imipramine, citalopram, 
escitalopram bupropion, sertraline 
Other drugs clopidogrel, warfarin, proguanil, 
chloramphenicol, propranolol, ritonavir, 
tolbutamid, cyclophosphamide 
16 
 
1.7. Cytochrome P 450 3A5 (CYP3A5) 
 
The CYP3A5 gene is one of the isoforms of CYP3A subfamily. CYP3A5, together with the 3A4, 
3A7 and 3A43 gene, belong to the CYP genes group, which are located in chromosome 7q21.1 
(Gellner K et al 2001). Considering that CYP3A5 belongs to the CYP3A enzymes and primarily 
is an extrahepatic enzyme, its variant alleles are likely to have an impact on the disposition of 
several xenobiotics and endogenous compounds in lung, kidney, prostate, breast and white blood 
cells, and therefore this fact can increase the possibility of developing pathologic conditions in 
these tissues (Peng et al., 2004). Because of the frequent mutation of adenosine to guanosine at 
position 6986 within intron 3 (rs776746), CYP3A5 is expressed in only 10% of Caucasians.   
The CYP3A5 enzyme contributes in the metabolism of more than half (>50%) of clinically used 
drugs and a number of procarcinogens and endogenous compounds, as well (Kuehl P et al 2001).  
The most important substrates of CYP3A5 are benzodiazepines (alprazolam, midazolam etc.), 
immunosuppressants (cyclosporine and tacrolimus), antibiotics/antivirals (clarithromycin, 
erythromycin, indinavir etc.), statins (atorvastatin), antipsychotics (quetiapine) and so on. A 
number of drugs can either induce or inhibit the activity of CYP3A5. The CYP3A5*1 allele (A at 
position 6989) encodes the production of normal mRNA, and resultantly it yields a high enzyme 
expression.   
On the other side, the main CYP3A5 gene variant alleles are *3 (6986A > G; rs776746) and *6 
allele (14690G>A; rs10264272). The CYP3A5*3 allele is characterized by alternative mRNA 
splicing. For that reason, the intron sequence is incorporated into the mature messenger RNA 
(mRNA), and, consequently, the premature completion of translation produces nonfunctional 
protein (Marwa KJ et al 2014). Individuals that are homozygous carriers of CYP3A5*3 allele 
(CYP3A5*3/*3) are known as non-expressers and lack protein activity compared to individuals 
that are known as expressers and are carriers of one CYP3A5*3 allele (CYP3A5*1*3) or 
completely lack this allele (CYP3A5*1*1). Carriers of CYP3A5*3/*3 genotype require lower 
doses of tacrolimus in order to achieve the target concentration as opposed to expressers 
(Hesselink, D. A. et al 2003). Additionally, the polymorphism of CYP3A5 *3 variant allele can 
also contribute as a risk factor in cancer developing (Sailaja K et al 2010). Additionally, the 
CYP3A5*6 variant allele (14690G>A) generates alternate splicing and thereafter protein 
truncation thus causing a full absence of CYP3A5 enzyme from a specific tissue. 
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The polymorphism of CYP3A5 gene is manifested with evident interethnic differences regarding 
the level of CYP3A5 enzyme (Bains RK et al 2013). Tacrolimus is the backbone therapy for 
immunosuppression after solid organ and hematopoietic stem cell transplantation. Extensive and 
intermediate metabolizers of CYP3A5 (CYP3A5*1/*1 and CYP3A5*1/*3) manifest a decreased 
dose-adjusted trough concentrations of tacrolimus compared to individuals that are CYP3A5 
nonexpressers/poor metabolizers (Birdwell, K. A. et al 2015). There are reports confirming the 
impact of interethnic difference on tacrolimus dosage after conversion from twice-a-day dosing 
of  tacrolimus (known also as Tac-BID) to once per day dosing (also known as Tac-OD) (Glick, 
L. et al 2014).  
In addition to polymorphism‟s impact, drug–drug interactions and environmental factors are 
important factors as well, contributing in these interethnic variations. Therefore, CYP3A5 is 
likely to be an important contributor in intra-ethnic and inter-ethnic differences of CYP3A 
mediated metabolism (Shirasaka Y et al 2013). Guidelines and recommendations have been 
issued for CYP3A5 and tacrolimus, (Birdwell KA et al 2015).  
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Table 5.  CYP3A5 enzyme main substrates 
Drug class 
Antidiabetics nateglinide 
Antimicrobics and antiprotozoals clarithromycin, dapsone, telithromycin, quinine 
Tyrosine kinase inhibitor imatinib 
Opioid analgesics alfentanil, cocaine, codeine, dextromethorphan, 
fentanyl, methadone, levomethadyl acetate 
Calcium channel blockers amlodipine, diltiazem, felodipine, lercanidipine, 
nifedipine, nisoldipine, nitrendipine, verapamil 
Benzodiazepines alprazolam, diazepam, midazolam, triazolam 
Antidepressants trazodone,  
Neuroleptics haloperidol 
Antihistamines astemizole, terfenadine 
Statins atorvastatin, cerivastatin, lovastatin, simvastatin,  
Antivirals indinavir, nelfinavir, ritonavir, saquinavir 
Chemotherapeutic and 
immunomodulatory drugs 
cyclosporine, paclitaxel, docetaxel, tamoxifen, 
irinotecan, vincristine, sirolimus, tacrolimus 
Other drugs aripiprazole, buspirone, caffeine, cilostazol, 
cisapride, domperidone, eplerenone, estradiol, 
finasteride, hydrocortisone, lidocaine, 
ondansetron, pimozide, progesterone, 
propranolol, salmeterol, sildenafil, testosterone, 
zaleplon, zolpidem 
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1.8. VKORC1 
 
 Apart from CYP2C9 and CYP2C19, warfarin metabolism is also influenced by vitamin K 
epoxide reductase complex 1 (VKORC1) that encodes the warfarin target protein (Wijnen PA et 
al. 2010; Suriapranata IM et al. 2011). Furthermore, this enzymatic complex (Rost S et al. 2004) 
recycles the reduced vitamin K, which is necessary for the posttranslational carboxylation of 
vitamin K-dependent clotting factors, such as prothrombin, FVII, FIX, and FX. The main variants 
of VKORC1 are VKORC1 [G3673A; (rs9923231)], VKORC1 [C6484T (rs9934438)] and 
VKORC1 [G9041A (rs7294)] (Owen RP et al 2010). Moreover, there is a strong linkage 
disequilibrium between the VKORC1 –1639G>A and 1173C>T polymorphisms (Seip RL et al. 
2010). These two polymorphisms manifest a direct impact on the effectiveness (potency) of a 
given dose of coumarin anticoagulant and on its response (D‟Andrea G et al. 2005; Zhu Y et al. 
2007). Studies on a Caucasian population have proved that in the cases of thromboembolic 
disorders, the carriers of the VKORC1 –1639 AA genotype require a significantly lower daily dose 
of warfarin compared to carriers of the GA or GG genotypes (Molden E et al. 2010). As for the 
VKORC1 –1639 AA genotype subjects, individuals with the TT genotype of VKORC1 (1173C>T) 
also require a lower warfarin maintenance dose compared to CC genotype (Yan X et al 2015). 
Clinical Pharmacogenetics Implementation Consortium (CPIC) published updated guidelines for 
pharmacogenetics-guided warfarin dosing which are valid for both pediatric and adult patients 
(Johnson JA et al 2017). Pharmacogenetics-guided dosing has been published for other 
anticoagulant such as acenocoumarol and phenprocoumon (Swen JJ et al 2011). 
 
 Table 6. Genes and variant alleles of cytochrome P450 and VKORC1 analyzed in 
this study 
Variant allele Single nucleotide base 
change 
Enzyme activity 
CYP 2C9 *2 c.430C> T Decreased  
CYP 2C9 *3 c.1075A >C Decreased  
CYP 2C19 *2 c.681G>A None 
CYP 2C19 *17 c.-806C>T Increased   
CYP3A5 *3 g.6986A > G none 
VKORC1 1173C>T Decreased  
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2. HYPOTHESIS  
 
Research conducted in other populations has shown that inter-ethnic differences of 
pharmacogenetic profile have a direct impact on pharmacotherapy. Thereby, we supposed that in 
Kosovo‟s population there are certain specificities of pharmacogenetic profile that deserve a 
closer examination.  
 
3. AIMS AND PURPOSE OF THE RESEARCH 
 
According to the present knowledge, the response to the clopidogrel, warfarin, NSAIDs, 
tacrolimus and imatinib pharmacotherapy is determined by a complex system of interactions at 
different levels; therefore, we supposed that predicting the CYPs and VKORC1 polymorphisms‟ 
value is important. In this context, we aimed to assign the frequency of major variant alleles of 
CYP2C9, CYP2C19, CYP3A5 and VKORC1 gene in order to use these data for identification of 
individuals of risk group, as well as mark them as potential molecular markers in 
pharmacodiagnostics and clinical practice. 
 
3.1. GENERAL AIM 
 
The main purpose of this study was to conduct a pharmacogenetic screening in Kosovo‟s healthy 
population. Information obtained from this research was used to compare the allele frequency in 
Kosovo‟s population with that of other ethnic groups.  
 
 
3.2. SPECIFIC AIM  
 
The more specific aim of this research was to investigate the frequency of CYP2C9, CYP2C19, 
CYP3A5 and VKORC1 polymorphisms in Kosovo‟s healthy population. 
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4. MATERIALS AND METHODOLOGY 
 
4.1 Research participants 
 
All participants have been enrolled provided that they sign a consent and information form. 
Research has commenced upon issuance of permission by the Ethics Committee of the University 
Clinical Center of Kosovo in Prishtina and the Faculty of Pharmacy in Skopje where all 
molecular analyses were performed. 
4.1.1. Healthy subjects 
 
The main criterion of inclusion in the research for this group of participants has been the absence 
of any mental illness or any history of serious physical illness based on individual's personal 
history. The distribution of allelic variants of CYP2C9, CYP2C19, CYP3A5 and VKORC1 in 
Kosovo‟s population has been analyzed in 234 people aged between 18 and 65 years. Research 
has been carried out in healthy persons without blood relationship between them, representing a 
mixed population from all the parts of Kosovo. The gender ratio of participants in the research 
was nearly equal between women and men (116:118).  
Research participants included mainly academic and non-academic staff of the Faculty of 
Medicine in Prishtina, medical and non-medical staff of the University Clinical Center of 
Kosovo, as well as medical and non-medical staff of the Main Family Medicine Center in 
Prishtina.  
 
4.2 Material 
 
Analytical samples 
 
In the process of DNA extraction (isolation), 5 ml of fresh blood together with the anticoagulant 
ethylene diamine tetra-acetic acid (EDTA) has been used from each research participant. Blood 
samples have been stored at -4°C for 3 days (maximum), until the analyses have been performed.  
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4.3 DNA analyses 
4.3.1 DNA isolation procedure 
Genomic DNA has been extracted from whole blood, using QIAGEN DNA extraction kit and the 
procedure recommended by the manufacturer (QIAGEN AS, Oslo, Norway). This method, which 
is based on cell lysis, enzymatic and chemical extraction, has been used in order to remove 
cellular proteins, ribonucleic acid (RNA), and other macromolecules. This has been followed by 
DNA precipitation in absolute alcohol.    
 
Laboratory equipments: 
 
1.  Microcentrifuge tube   Eppendorf AG, Germany 
2.  QIAamp Mini spin column (2ml)  Qiagen GmbH, Germany 
3.  Collection tubes (2ml)  Qiagen GmbH, Germany 
4.  Refrigerated Centrifuge  Centurion Scientific, UK 
5.  Dry block thermostat at 56º C BioSan, Latvia 
6.  Vortexer 2x3  UNI EQUIP, Germany 
7.  Microcentrifuge (with rotor for 2ml tubes)  Mini spin plus, Germany 
8.  Automatic Pipettes Eppendorf research  Thermo Scientific, USA 
9.  Pipet tips with aerosol barrier Top- Line  Germany 
        (QIAamp DNA mini handbook, page no 16) 
 
 
Materials 
 
1.  QIAGEN Proteinase K (store at 2-8°C or -
20°C), 
 
As indicated on the label, when using the 
QIAamp DNA blood mini kit (250), 5.5 ml of 
protease solvent should be pipetted into the vial 
containing lyophilized QIAGEN protease. 
Qiagen GmbH, Germany 
2.  Buffer AL  GmbH, Germany 
3.  Ethanol (96-100%) Alkaloid, Macedonia 
4.  Buffer AW1 GmbH, Germany 
5.  Buffer AW2  GmbH, Germany 
6.  Buffer AE GmbH, Germany 
           (QIAamp DNA mini handbook, page no 27) 
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Procedure 
 
1. 20 μl of QIAGEN Protease (or proteinase K) should be pipetted into the bottom of the 1.5 
ml microcentrifuge tube. 
2. Thereafter, 200 μl of the sample (participant‟s blood) should be added into the 
microcentrifuge tube. 
3. 200 μl of Buffer AL should be pipetted into the 1.5 ml microcentrifuge tube together with 
participant‟s sample and QIAGEN Protease. After that, this mixture should be mixed by pulse-
vortexer for 15 seconds. 
4. Mixture should be incubated at 56°C for 10-20 minutes. 
5. The 1.5 ml microcentrifuge tube should be briefly centrifuged in order to remove drops 
from the inside of the lid. 
6. 200 μl ethanol (96-100%) should be pipetted to the sample, and mixed again by pulse-
vortexing for 15 seconds. After mixing, the 1.5 ml microcentrifuge tube should be centrifuged 
briefly to remove drops from the inside of the lid.  
7. In case the volume is more than 200 μl, the amount of the ethanol should be increased 
proportionally. Example: 300 μl of ethanol should be pipetted into 300 μl of sample. 
8. The mixture obtained from step six carefully should be applied to the QIAamp Mini spin 
column (2ml), but being careful not to wet the rim. After that, the cap of the Mini spin column 
(QIAGEN) should be closed and centrifuged at 8000 rpm for 1 minute (60 seconds). This 
column should be placed in a clean 2ml collection tube to remove the filtrate from the tube. 
9. The QIAamp Mini spin column should be opened cautiously and after that add 500 μl 
Buffer AW1 carefully without wetting the rim. The cap of the column should be closed and 
centrifuged at 8000 rpm for 1 minute. QIAamp Mini spin column should be placed in a clean 2 
ml collection tube, while discardind the filtrate from the collection tube. 
10. The QIAamp Mini spin column should be opened cautiously and add 500 μl Buffer AW2 
without wetting the rim. After closing the cap, it should be centrifuged at full speed (14000 
rpm) for 3 min.  
11. Recomended. The QIAamp Mini spin column (not provided) should be placed in a new 2 
ml collection tube,  and the filtarte from the old collection tube discarded. Centrifuge the 
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column at full speed for 1 minute. This procedure makes possible to avoid the eventual 
carryover of Buffer AW2. 
12. The QIAamp Mini spin column (not provided) should be placed in a clean 1.5 ml 
microcentrifuge tube and then discard the filtrate from the collection tube. The QIAamp Mini 
spin column should be opened cautiously and add either 200 μl Buffer AE or distillated water. 
Thereafter it should undergo incubation at room temperature (15-25 °C) for 1 minute, and then 
centrifuged at 8000 rpm for 1 minute. 
 
 
4.3.2 Determination of DNA yield, concentration and purity 
 
DNA yield (from the concentration of DNA in the eluate) was determined diluting the solution in 
the ratio 1:100 with TE buffer and absorbance (A) has been measured spectrophotometrically at 
wavelength 260 nm:  
CDNA = dilution x F x A = 100 x 50 x A 
Purity was determined calculating the ratio of absorbance at 260 ηm to absorbance at 280 ηm. 
Pure DNA has an A260/A280 ratio of 1.7-1.9.  
 
 
4.3.3 Testing of the quality of isolated DNA 
 
The quality of isolated DNA has been tested by electrophoresis in 0.3% agarose gel with 
ethidium bromide. 
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Procedure 
1. First, we should add 1 g of agarose in 200 ml of distilled water. 
2. In the second step, in the microwave, the solution should be heated to boiling in order to 
dissolve the agarose. Subsequently, 400 µL 50x TEA- buffer and 2.8 ml of ethidiume bromide 
should be added. 
3. Samples containing 9μL of DNA solution in TE buffer and 1μL buffer with color should be 
applied on the molded and prepared gel. Terms of electrophoresis: 40 V. 
4. The conduction of DNA fragments detection is performed under a fluorescent lamp and the 
documentation of the results is carried out in a photography Polaroid film 667. 
Materials: 
1. 0.3% agarose gel  
Agarose                                                              0.6 (BioRad, USA) 
Distilled water  up to                                         200 ml (Alkaloid, Macedonia) 
2. Ethidium bromide                                           10 mg/ml (Sigma Aldrich Chemie, USA) 
3. 50x TEA buffer   
Tris or Tris(hydroxymethyl)aminomethane 242 g (Sigma Life Science, USA) 
EDTA [500mM (pH 8.0) solution] 100 mL (Sigma Aldrich, USA) 
Acetic acid 57,1 mL (Alkaloid, Macedonia) 
Distilled water  up to 1000 ml (Alkaloid, Macedonia) 
4. 1x TEA- buffer: 20 ml 50x TEA+ 200 µL 
Ethidium-bromide (10 µL/mL), add 1000ml water 
 
5. The buffer for the sample application on the gel  
Bromophenol blue  1 %                 1 mL (Merck, Germany) 
Xylene cyanol  1%                1mL (Sigma Aldrich, USA) 
Glycerol 50 %                                   5 mL (Merck, Germany) 
50x TEA- buffer  2 %                           190 µL (Merck, Germany) 
Distilled water                    2,75 mL (Alkaloid, Macedonia) 
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4.4. Genotyping methods  
 
Materials used for DNA molecular analyses: 
 
TaqMan Universal PCR Master Mix (5x5mL, 1000 rnx)                  Applied Biosystems, USA                                                                                                      
(Thermo Fisher Scientific) 
KIT, TAQMAN DRUG METABOLISM                                           
 
Applied Biosystems, USA                                                                                                             
(Thermo Fisher Scientific) 
Multiplate 96-Well PCR Plates, natural, 25                                         
 
Applied Biosystems, USA                                                                                                             
(Thermo Fisher Scientific) 
Optical Flat 8-Cap Strips, for 0.2 ml tubes and plates, 
ultraclear, 120 units                                                                             
Applied Biosystems, USA 
(Thermo Fisher Scientific) 
Primers 25 nmol                                                                                     
 
Invitrogen, USA 
(Thermo Fisher Scientific) 
QIAGEN Protease                                                                                 QIAGEN, Germany 
 
Equipment used for DNA molecular analyses 
 
Stratagene™ Mx3005P qPCR Instrument                                       
 
Agilent Technologies, USA 
Centrifuge                                       
 
Beckman, Eppendorf, Germany 
Spectrophotometer NanoDrop 2000                                                 
 
Thermo Scientific, USA 
Erlenmeyer flask                                                                               
 
Isolab, Germany 
Microwave oven                                                                               
 
Gorenje, Slovenia 
Electrophoresis system                                                                     
 
Mini-Sub
®
 Cell GT, USA 
Molecular imager VersaDoc MP 4000 system                                 
 
Bio-Rad Laboratories, USA 
Cleanroom Bench BIOSAFE                                                           
 
Ehret, Germany 
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4.4.1 Real time-PCR 
 
Genotyping of CYP2C9, CYP2C19, CYP3A5 and VKORC1 has been carried out using ABI 
TaqMan assays on Stratagene RealTime PCR machine. The single nucleotide polymorphisms 
(SNPs) in CYP2C9, CYP2C19, CYP3A5 and VKORC1 genes has been analyzed by allelic 
discrimination TaqMan assay (Applied Biosystems, Foster City, CA, USA) using the TaqMan 
DME genotyping assay according to the manufacturer‟s instructions (Applied Biosystems, Foster 
City, CA, USA). The basic principle of PCR is the exponential multiplication of genes of interest 
within the DNA molecules. In order to multiply certain DNA segment, 2 µl of DNA together with 
10,5 µl PCR mix {3,625 µl H2O, 6,25 µl master-mix [DNA polymerase, deoxyadenosine 
triphosphate (dATP), deoxythymidine triphosphate (dTTP), deoxyguanosine triphosphate (dGTP) 
and deoxycytidine triphosphate (dCTP) ] and 0.625 µl of gene specific primer} underwent 
incubation according to specific conditions. The PCR procedure contains three main steps during 
each cycle: 
Step 1 (Denaturation of DNA): Incubation in high temperature (till 95°C) is used to “melt” DNA 
from double-stranded into single strands as well as to lose secondary structure in single strands of 
sample's DNA. The maximum temperature during reaction's cycle in which DNA polymerase is 
still active is 95°C. If the guanine-cytosine content (GC content) of template is high, we might 
have an increase in denaturation time.  
Step 2 (Annealing): During this step of reaction, at 54°C, hybridisation between complementary 
segment of single stranded of DNA and specific primer occurs.   
Step 3 (Extension): With contribution of the DNA polymerase, at 72°C, extension of primer 
occurs at rates of up to 100 nucleotide bases/sec and consequently is synthesized complementary 
stranded of DNA. In cases when an amplicon of Real-time PCR reaction is small, this phase of 
reaction at 60°C, usually is combined with the annealing phase of reaction.     
In the next cycle of reaction, the newly created DNA molecules become “pattern”. In order to 
obtain sufficient material for further genetic analysis, multiplication was performed through 50 
cycles.  
1. During cooling cycles, ahead to the extension phase, hybridisation of TaqMan probe to its 
complementary segment in the amplicon of PCR occurs. 
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2. Throughout polymerisation, when there is an encountering between Taq polymerase and 
TaqMan probe, 5‟ to 3‟ exonuclease activity results in the digestion of the reaction probe. 
3. Hence, this process separates the donor (FAM) from the acceptor (TAMRA) of fluorescence 
and subsequently excitation at 495 nm is followed by the fluorescence emission by FAM at 
wavelength of 525nm.    
4. Considering that in this momentum two fluorescent dyes are in a considerable distance from 
each other, energy transfer from FAM to TAMRA dye cannot happen. 
5. Hence, when TaqMan probe has been digested, fluorescence of the TAMRA dye does not 
occur. 
6. In general, the increase of fluorescence emission at 525nm wavelength, on the one hand, 
and a decrease of fluorescence emission at 585 nm wavelength, on the other, is an indicator of 
a positive PCR reaction. 
In each PCR reaction, genomic DNA, specific primers, DNA polymerase concentration, Mg
++
 
(magnesium ions), as well as time and temperature for each step of the reaction, depends on 
the analytical system and are tested for every segment of genomic DNA. 
 
Chemicals and equipment used for genotyping  
 
1) deoxyribonucleotide triphosphates (dATP, dGTP, dCTP and dTTP) 
- 6,5 µl PCR Master Mix, 2X (50 units/ml of Taq DNA polymerase supplied in a proprietary 
reaction buffer (pH 8.5), 400μMdATP, 400μM dGTP, 400μM dCTP, 400μM dTTP, 3mM 
MgCl2. 
2) 3,625 µl distillated H2O 
3) 0.625 µl of gene specific primer  
4) 2 µl of DNA 
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Figure 1. Schematic description of a TaqMan® Drug Metabolism Genotyping 
Assay (Reference Guide, Applied Biosystems) 
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4.4.1.1 CYP2C9 genotyping 
4.4.1.1.1 Genotyping for the *2 variant allele of CYP2C9 
For multiplication of the CYP2C9*2 variant, 2 µl of participant‟s genomic DNA together with 
10,5 µl PCR mix [3.625 µl H2O, 6.25 µl master-mix (DNA polymerase, dATP, dTTP, dGTP, 
dCTP) and 0.625 µl of gene specific primer] underwent incubation according to specific 
conditions.  
Real Time PCR thermal conditions for CYP2C9*2 variant were:  
2 minutes (50°C)  
10 minutes (95°C),  
15sec (92°C) 50 cycles 
 60sec (60°C)  
Table 7.  CYP2C9*2  variant 
 
CYP2C9*2  (*2 allele) 
SNP ID: rs1799853 
Assay code: C_25625805_10   
Gene: CYP2C9 
Gene Name:  cytochrome P450, family 2, subfamily C, polypeptide 9 
Set Membership: > HapMap > DME > Validated > Inventoried 
Chromosome Location:  Chr.10: 96702047 - 96702047 on NCBI Build 37 
Polymorphism: C/T, Transition Substitution 
Context sequence [VIC/FAM]  is C/T 
GATGGGGAAGAGGAGCATTGAGGAC[C/T]GTGTTCAAGAGGAAGCCCGCTGCCT 
T-allele frequency in Caucasians is 0.17 (or 17%) 
 C/C- Homozygous for normal allele  
C/T- Heterozygous for variant allele 
T/T- Homozygous for variant allele 
 
Total number of samples = 234 
C/C=160 Samples 
C/T=66 Samples (66 variant alleles) 
T/T= 8 Samples (16 variant alleles) 
 
T allele frequency in this study = 82/468 = 17,52% 
(https://www.thermofisher.com/order/genome-database/browse/snp/keyword/C__25625805_10)_ 
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Real-time PCR result for CY2C9*1*2  
(heterozygous for variant*2) 
 
 
 
 
 
  Figure 2. 
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Real-time PCR result for CY2C9*2*2  
(homozygous for variant *2) 
 
 
 
 
 
         
 
 
Figure 3. 
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4.4.1.1.2 Genotyping for the *3 variant allele of CYP2C9 
 
In order to multiply the CYP2C9*3 variant, 10,5 µl PCR mix [3.625 µl H2O, 6.25 µl master-
mix (DNA polymerase, dATP, dTTP, dGTP, dCTP) and 0.625 µl of gene specific primer] 
together with 2 µl of participant‟s DNA underwent incubation according to specific 
conditions.  
Thermal conditions of Real Time PCR for variant *3 of CYP2C9 were:  
2 minutes (50°C)  
10 minutes (95°C),  
15sec (92°C) 50 cycles 
 60sec (60°C)  
Table 8. CYP2C9*3  variant 
 
SNP ID: rs1057910 
Assay code: C_27104892_10   
Gene: CYP2C9 
Gene Name:  cytochrome P450, family 2, subfamily C, polypeptide 9 
Set Membership: > HapMap > DME > Validated > Inventoried 
Chromosome Location:  Chr.10: 96741053 - 96741053 on NCBI Build 37 
Polymorphism: C/A, Transversion Substitution  
Context Sequence [VIC/FAM]: C/A 
TGTGGTGCACGAGGTCCAGAGATAC[C/A]TTGACCTTCTCCCCACCAGCCTGCC 
C-allele frequency in Caucasians is 0.1 (or 10%) 
 
A/A- Homozygous for normal allele  
C/A- Heterozygous for variant allele 
C/C- Homozygous for variant allele 
 
Total number of samples = 234 
A/A= 187 Samples 
C/A= 43 Samples (43 variant alleles) 
C/C= 4 Samples (8 variant alleles) 
 
C allele frequency in this study =51/468=10,89% 
(https://www.thermofisher.com/order/genome-database/browse/snp/keyword/C_27104892_10) 
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Real-time PCR result for CY2C9*1*3  
(heterozygous for variant *3) 
  
 
 
 
  
    Figure 4. 
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Real-time PCR result for CY2C9*3*3  
(homozygous for variant *3) 
 
 
 
 
 
Figure 5. 
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4.4.1.2 CYP2C19 genotyping 
4.4.1.2.1 Genotyping for the *2 variant allele of CYP2C19 
 
To multiply the *2 variant of CYP2C19, 10,5 µl PCR mix [3.625 µl H2O, 6.25 µl master-mix 
(DNA polymerase, dATP, dTTP, dGTP, dCTP) and 0.625 µl of gene specific primer] together 
with 2 µl of participant‟s DNA underwent incubation according to specific conditions.  
Real Time PCR thermal conditions for variant *2 of CYP2C19 were:  
2 minutes (50°C)  
10 minutes (95°C),  
15sec (92°C)       50 cycles 
 60sec (60°C)  
Table 9.  CYP2C19*2 variant 
SNP ID: rs4244285 
Assay code: C_25986767_70   
Gene: CYP2C19 
Gene Name:  cytochrome P450, family 2, subfamily C, polypeptide 19 
Set Membership:  > HapMap > DME > Validated > Inventoried 
Chromosome Location: Chr.10: 96541616 - 96541616 on NCBI Build 37 
Polymorphism:  A/G, Transition Substitution 
Context sequence [VIC/FAM]  is A/G 
TTCCCACTATCATTGATTATTTCCC[A/G]GGAACCCATAACAAATTACTTAAAA 
A-allele frequency in Caucasians is 0.14 (or 14%) 
 
G/G-Homozygous for normal allele  
A/G-Heterozygous   
A/A-Homozygous for variant allele  
 
Total number of samples = 234 
G/G=178 Samples 
A/G=51 Samples (51 variant alleles) 
A/A= 5 Samples (10 variant alleles) 
 
A allele frequency in this study =61/468=13,03% 
(https://www.thermofisher.com/order/genome-database/browse/snp/keyword/C_25986767_70) 
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Real-time PCR result for CY2C19*1*2  
(heterozygous for variant *2) 
 
 
 
 
 
 
 
Figure 6. 
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Real-time PCR result for CY2C19*2*2  
(homozygous for variant *2) 
 
 
 
 
 
Figure 7. 
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4.4.1.2.2 Genotyping for the *17 variant allele of CYP2C19 
 
For multiplication of the *17 variant of CYP2C19, 2 µl of participant‟s DNA with 10,5 µl PCR 
mix [3.625 µl H2O, 6.25 µl master-mix (DNA polymerase, dATP, dTTP, dGTP, dCTP) and 
0.625 µl of gene specific primer] underwent incubation according to specific conditions.  
Real Time PCR thermal conditions for variant *17 of CYP2C9 were:  
2 minutes (50°C)  
10 minutes (95°C),  
15sec (92°C) 50 cycles 
 60sec (60°C)  
Table 10. CYP2C19* 17 variant   
SNP ID: rs12248560 
Assay code: C_469857_10   
Gene: CYP2C19 
Gene Name:  cytochrome P450, family 2, subfamily C, polypeptide 19 
Set Membership:  > HapMap > DME > Validated > Inventoried 
Chromosome Location: Chr.10: 96521657 - 96521657 on NCBI Build 37 
Polymorphism: C/T, Transition Substitution 
Context sequence [VIC/FAM]  is C/T 
AAATTTGTGTCTTCTGTTCTCAAAG[C/T]ATCTCTGATGTAAGAGATAATGCGC 
T-allele frequency in Caucasians is 0.17 (or 17%) 
 
C/C-Homozygous for normal allele  
C/T-Heterozygous   
T/T-Homozygous for variant allele  
 
Total number of samples = 234 
C/C= 155 Samples 
C/T= 69 Samples (67 variant alleles) 
T/T= 10 Samples (20 variant alleles) 
 
T allele frequency in this study = 89/468 = 19,01% 
(https://www.thermofisher.com/order/genome-database/browse/snp/keyword/C_469857_10) 
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Real-time PCR result for CY2C19*2*17  
(heterozygous for variant *17) 
 
 
 
 
Figure 8. 
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Real-time PCR result for CY2C19*17*17  
(homozygous for variant *17) 
 
 
 
 
 
 
 
Figure 9. 
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4.4.1.3  CYP3A5*3 genotyping 
 
Multiplication of the CYP3A5*3 variant, was performed using 10.5 µl PCR mix [3.625 µl 
H2O, 6.25 µl master-mix (DNA polymerase, dATP, dTTP, dGTP, dCTP) and 0.625 µl of gene 
specific primer] together with 2 µl of participant‟s DNA and thereafter undergoing incubation 
according to specific conditions.  
Real Time PCR thermal conditions for CYP3A5*3 variant were:  
2 minutes (50°C)  
10 minutes (95°C),  
15sec (92°C) 50 cycles 
 60sec (60°C)  
Table 11. CYP3A5* 3  variant 
SNP ID: rs776746 
Assay code: C_26201809_30   
Gene: CYP3A5 
Gene Name:  cytochrome P450, family 3, subfamily A, polypeptide 5 
Set Membership:  > HapMap > DME > Validated > Inventoried 
Chromosome Location:  Chr.7: 99270539 - 99270539 on NCBI Build 37 
Polymorphism: T/C, Transition Substitution 
Context sequence [VIC/FAM]  is T/C 
ATGTGGTCCAAACAGGGAAGAGATA[T/C]TGAAAGACAAAAGAGCTCTTTAAAG 
T-allele frequency in Caucasians is 0.01 (or 1%) 
 
C/C-Homozygous for variant allele  
T/C-Heterozygous   
T/T-Homozygous for normal allele  
 
Total number of samples = 234 
C/C=230 Samples (460 variant alleles) 
T/C=0 Samples (0 variant alleles) 
T/T= 4 Samples  
 
C allele frequency in this study=460/468=98.3% 
T =8/468=1,7% 
 
(https://www.thermofisher.com/order/genome-database/browse/snp/keyword/C_26201809_30) 
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Real-time PCR result for CY3A5*3*3  
(homozygous for variant *3) 
 
 
 
 
 
 
  
 
 
Figure 10. 
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Real-time PCR result for CY3A5*1*1  
(homozygous for normal allele) 
 
 
 
 
  
Figure 11. 
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4.4.1.4 VKORC1 (1173C>T) genotyping 
 
In order to multiply VKORC1 (C>T), 10,5 µl PCR mix [3.625 µl H2O, 6.25 µl master-mix 
(DNA polymerase, dATP, dTTP, dGTP, dCTP) and 0.625 µl of gene specific primer] together 
with 2 µl of participant‟s DNA, underwent incubation according to specific conditions.  
Real Time PCR thermal conditions for VKORC1 (C>T) were:  
2 minutes (50°C)  
10 minutes (95°C),  
15sec (92°C) 50 cycles 
 60sec (60°C) 
Table 12. VKORC1   (1173C>T or C6484T) 
SNP ID: rs9934438 
Assay code: C_30204875_10   
Gene: VKORC1 
Gene Name:  protease, serine, 53 
Set Membership:  > HapMap > DME > Validated > Inventoried 
Chromosome Location: Chr.16: 31104878 - 31104878 on NCBI Build 37 
Polymorphism: A/G, Transition Substitution 
Context sequence [VIC/FAM]  is A/G 
CCCCGACCTCCCATCCTAGTCCAAG[A/G]GTCGATGATCTCCTGGCACCGGGCA 
A-allele frequency in Caucasians is 0.38 (or 38%) 
 
G/G-Homozygous for normal allele  
G/A-Heterozygous   
A/A-Homozygous for variant allele  
 
Total number of samples = 234 
G/G=78 Samples 
G/A=121 Samples (121 variant alleles) 
A/A= 35 Samples (70 variant alleles) 
 
A allele in this study=191/468=40,81% 
(https://www.thermofisher.com/order/genome-database/browse/snp/keyword/C_30204875_10) 
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Real-time PCR result for VKORC1 (A/A)  
(homozygous for variant allele) 
 
  
 
 
 
 
 
 
Figure 12. 
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Real-time PCR result for VKORC1 (G/A)  
(heterozygous for variant allele) 
 
 
 
 
 
 
Figure 13.  
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Real-time PCR result for VKORC1 (G/G)  
(homozygous for normal allele) 
 
 
 
 
  
Figure 14. 
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4.5 STATISTICAL ANALYSIS 
 
 
This study‟s statistics were conducted through a descriptive analysis of all the analyzed variables. 
The gene-counting method was used to estimate the allele frequency. Likewise, this study 
compared the observed allele and genotype frequency and expected allele and genotype 
frequencies according to the Hardy-Weinberg equilibrium. The frequency of specific genotypes 
and haplotypes in healthy Kosovo population and other populations was compared using the 
proportion test. Chi-squared test and proportion test were used in analysing frequency and 
distribution of genotypes as well as phenotyping groups such as extensive, intermediate, ultra-
extensive and poor metabolizers. In addition, a 95% confidence interval was assigned. 
Interpretation of results is set at a 5% significance level (p<0,05). The SPSS statistical (SPSS 
Inc., Chicago, IL, USA, 20.0 version) program and the online calculator (Link 5) were used for 
conducting statistical data processing. 
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5.  RESULTS 
 
Table 13. 
Demographic data regarding the study group’ 
participants 
Total number of 
participants 
234 
Sex (male/female) 118/116 
Age (years) (mean ± 
SD) 
36.01 ± 12.70 
Age range (years) 20 - 65 
 
 
5.1 Frequency of CYP2C9, CYP2C19, CYP3A5 and VKORC1 polymorphism in 
Kosovo's healthy population 
 
Genotyping for CYP2C9, CYP2C19, CYP3A5 and VKORC1 was conducted in 234 healthy 
Kosovo's healthy volunteers. Statistical analysis of the results was performed in order to find out 
the eventual difference between Kosovars and other populations regarding their genotypes and 
haplotypes.  In addition, it was investigated whether there is any difference in genotypes and 
haplotypes between male and female participants of this study. 
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Table 14.   CYP2C9  genotype, allele and predicted phenotype frequencies in Kosovo’s population 
Gene Genotype Number 
of 
subjects 
(n) 
Observed 
frequency 
(%) 
95% 
Confidence 
Interval 
Predicted 
phenotype 
Investigated 
Allele 
Number  
(2n) / (%) 
CYP2C9 
CYP2C9*1*1 117 50,00 43.59-56.41 EM CYP2C9*1 335 (71.58) 
CYP2C9*1*2  62 26,49 20.84-32.14 IM CYP2C9*2 82 (17,52) 
CYP2C9*1*3 39 16,66 11.89-21.43 IM CYP2C9*3 51 (10,89) 
CYP2C9*2*2  8 3.41 1.08-5.74 PM    
CYP2C9*2*3  4 1,70 0.04-3.36 PM  
CYP2C9*3*3  4 1,70 0.04-3.36 PM  
Total  234 subjects      
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Table 15.   CYP2C9 genotype frequencies in Kosovo’s population compared to other countries’ 
CYP2C9 
genotype 
This 
study 
(%) 
Croatia Macedonia 
(%) 
Greece 
(%) 
Slovenia 
(%) 
UK 
(%) 
Belgium 
(%) 
Russia 
(%) 
Sweden 
(%) 
Argentina 
(%) 
Africa 
(%) 
Japan 
(%) 
CYP2C9*1*1 50,00 59.72 57.4 62 66.6 70.0 67 68 66.7 56 93.6 95 
CYP2C9*1*2 26.49 23.52 21.6 20 19.4 14.2 18,2 18.2 18.6 23 4.2 0 
CYP2C9*1*3 16,66 12.78 11.3 13.5 10.8 14.2 11,3 11.3 11.6 5 2.1 4 
CYP2C9*2*2 3.41 1.76 2.84 1.5 1.5 0.8 0 0.6 0.4 14 0 0 
CYP2C9*2*3 1.70 1.94 1.13 2.8 1.5 0.8 1,6 1.2 1.6 1 0 0 
CYP2C9*3*3 1.70 0.28 1.13 0 0 0 0,8 0.3 0.6 0 0 1 
Total 234 1080 179 283 129 120 121 290 430 101 47 828 
Reference - [a] [j] [b] [c] [d] [e] [f] [f] [g] [h] [i] 
 
a-Ganoci L,  Bozina N et al 2017; b- Arvanitidis K et al 2007; c- Herman D et al 2003; d- Biss TT et al 2011; e-  Buzoianu, A. D. et al 2012; f- 
Azarpira N et al 2010; g- Scibona P et al 2012; h- Isaza C et al 2007; i- Mushiroda T, et al 2006; j- Jakovski K et al 2013; 
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Table 16.   CYP2C9  allele frequencies in  Kosovo’s population compared to other countries’ 
CYP2C9 
allele 
This 
study 
(%) 
Croatia Slovenia 
(%) 
Macedonia 
(%) 
Greece 
(%) 
France 
(%) 
Romania 
(%) 
China 
(%) 
Japan 
(%) 
Benin 
(Africa) 
(%) 
Iran 
(%) 
Argentina 
(%) 
*1 71.58 79 81,7 78.8 79 77 79.4 96.3 97,6 95,5 64,8 70,79 
*2 17,52 14 12 13.9 12.8 15 11.3 0.1 0 0 25,3 25,74 
*3 10,89 7 6,2 7.3 8,1 8 9.3 3.6 2,3 0 9,8 2,97 
Total 234 200 129 179 283 151 332 394 828 111 150 101 
Reference - [a] [c] [d] [b] [h] [e] [j] [i] [e] [f] [g] 
 
a-Ganoci L,  Bozina N et al 2017; b- Arvanitidis K et al 2007; c- Herman D et al 2003;  d- Jakovski K et al 2013; e-  Buzoianu, A. D. 
et al 2012; f- Azarpira N et al 2010; g- Scibona P et al 2012;  h-Yang JQ et al 2003; i- Mushiroda T, et al 2006;  
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Table 17.    Genotype, allele and predicted phenotype frequencies of CYP2C19 in the Kosovo population 
Gene Genotype Number 
of 
subjects 
(n) 
Observed 
frequency 
(%) 
95% 
Confidence 
Interval 
Predicted 
phenotype 
Investigated 
allele 
Number  
(2n) / (%) 
CYP2C19 
CYP2C19*1*1 107 45,72 39.34-52.1 EM CYP2C19*1 318 (67.94)   
CYP2C19*1*2 43 18,37 13.41-23.33 IM CYP2C19*2 61 (13,03)  
CYP2C19*2*2 5 2,13 0.28-3.98 PM CYP2C19*17 89 (19,01) 
CYP2C19*2*17 8 3,41 1.08-5.74 IM   
CYP2C19*1*17 61 26,06 20.44-31.68 UM   
CYP2C19*17*17 10 4,27 1.68-6.86 UM   
Total  234 subjects    
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Table 18.    CYP2C19 genotype frequencies  in  Kosovo’s population compared to other countries’ 
CYP2C19 
genotype 
This study 
(%) 
Greece 
(%) 
Macedonia 
(%) 
Croatia Russia 
(%) 
Slovenia 
(%) 
Iran 
(%) 
Mexico 
% 
Italy 
(%) 
Colombia 
(%) 
India 
(%) 
China 
(%) 
*1*1 45.72 44.17 41.8 36.03 32.65 68.2 41.7 60.08 79.4 83.5 16.1 42 
*1*2 18.37 17.8 19.0 19.56 16.99 30 18.3 13.03 18.8 15.3 31.0 41 
*2*2 2.13 2.1 2.7 2.4 1.44 0.7 2.2 0.42 0 1 18.4 3 
*1*17 26.06 28.6 28.3 31.34 32.95 / 28.8 21.01 / / 20.7 4 
*2*17 3.41 4.3 4.3 5.29 8.03 / 3.3 3.36 / / 12.6 2 
*17*17 4.27 3.2 3.8 5.39 6.79 / 5.5 2.1 / / 1.2 / 
Total 234 283 184 1002 971 129 180 238 360 189 20 100 
Reference - (a) (b) (k) (c) (e) (d) (f) (g) (h) (i) (j) 
 
a-Ragia G et al 2009;  b- Jakovski K et al 2013; c- Sychev DA et al 2015; d- Payan M et al 2015; e- Herman D et al 2003; f- Favela-Mendoza AF et al 
2015; g- Scordo MG et al 2004; h- Isaza C et al 2007; i- Anichavezhi D et al 2012; j- Zhou Q et al 2009; k-Ganoci L, Bozina N et al, 2017 
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Table 19.    CYP2C19  allele frequencies in  Kosovo’s population compared to other countries’ 
CYP2C19 
allele 
This 
study 
(%) 
Greece 
(%) 
Sweden 
(%) 
Croatia 
(%) 
Macedonia 
(%) 
Faroe 
Island 
(%) 
Mexico 
(%) 
China 
(%) 
Tibet 
(%) 
Iran 
(%) 
 
Africa 
(%) 
Japan 
(%) 
India 
(%) 
*1 68.16 67.32 64 61.3 65.4 65.9 77.10 67.50 78.13 65.3 63.0 58 42.0 
*2 13.03 13.07 16 15 14.4 18.7 8.61 25.5 15.1 13.1 12.0 27.9 40.2 
*17 19.01 19.61 20.0 23.7 20.2 15.4 14.29 3.0 1.56 21.6 19.0 1.3 17.9 
Total 234 283 185 1002 184 312 238 100 96 180 149 265 216 
Reference - (a) (k) (e) (b) (l, m) (f) (j) (g) (h) (c) (d) (i) 
 
a-Ragia G et al 2009;  b- Jakovski K et al 2013; c- Strom CM et al 2012; d- Sugimoto K et al 2008; e-Ganoci L, Bozina N et al, 2017; f- 
Favela-Mendoza AF et al 2015; g- Jin T et al 2016;  h-Payan M et al 2015; i- Anichavezhi D et al 2012; j- Zhou Q et al 2009; k- Ramsjö 
M et al 2010;  l-Halling J et al 2005; m- Kurose K et al 2012;  
 
 
 
 
 
 
57 
 
Table 20.   CYP3A5  genotype frequency in Kosovo’s population 
Genotype Number of 
subjects 
(n) 
 
Observed 
frequency 
(%) 
95% 
Confidence 
Interval 
Predicted 
phenotype 
Investigated  
allele 
Number  
(2n) / (%) 
*1/*1 4  1.7 0.04-3.36 expressor CYP3A5*1 8 (1.7) 
*1/*3 0 0 0 expressor CYP3A5*3 460 (98.3) 
*3/*3 230 98.3 96.64-99.96 non-expressor   
Total 234      
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Table 21.  CYP3A5*3 variant frequency (6986A>G)  in Kosovo and other countries population 
CYP3A5 Present study Macedonia Poland Greece Tanzania/ 
(Afro-
Americans) 
China India Sweden 
1* 1.7% 
 
1.1% 
 
 
6% 
 
 
5.7 % 
 
51.0% 24.5% 40.6% 7 % 
3* 98.3 % 90.8 % 
 
94 % 
 
94,3 % 
 
19.0 % 
 
75.5 % 59.4% 93 % 
n 234 194 200 283 144 108 90 136 
Reference - [a] [b] [c] [d] [e] [e] [d] 
 
a-Jakovski K et al 2012; b- Adler G et al 2009; c- Arvanitidis K et al 2007; d- Mirghani RA et al 2006; e- Balram C et al 
2003. 
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Table 22.   VKORC1 genotype and variant allele frequency  in  Kosovo’s population 
Genotype Number/ (%) Allele 2n / % 
TT  (or AA) 35 (14.95) C 277 (59.19) 
CT  (or AG) 121 (51.70) T 191 (40,81) 
CC  (or GG) 78 (33,33)  
Total 234  
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Table 23.   VKORC1  genotype and allele frequencies in Kosovo compared to other countries’ population 
SNP 
Genotype 
/ 
allele 
Ethnic group 
Present 
study 
Croats 
(a) 
Italians 
(b) 
Chinese 
(c) 
Australians 
(d) 
Japanese 
(e) 
African 
Americans 
(f) 
n / (%) n / (%) n / (%) n / (%) n / (%) n / (%) n / (%) 
VKORC1 
1173C >T 
CC 78 (33.33) 63 (33.9%) 114 (43.2) 0 (0.00) 6 (35.29) 2 (1.25) 181 (80.4) 
CT 121 (51.70) 87 (46.8%) 116 (43.9) 47 (16.91) 6 (35.29) 22 (13.75) 42 (18.7) 
TT 35 (14.95) 36 (19.4%) 34 (12.9) 231 (83.09) 5 (29.41) 136 (85) 2 (0.9) 
C (2n) 277 (59.19) 213 (57.25%) 344 (65.15) 47 (8.46) 18 (52.94) 26 (8.13) 404 (89.78) 
T (2n) 191 (40,81) 159 (42.74) 184 (34.85) 509 (91.54) 16 (47.05) 294 (91.87) 46 (10.22) 
 Total (n) 234 186 264 278 17 160 225 
 
a- Mandic D et al, 2015; b- Mazzaccara C et al 2013; c-Yan X et al, 2015; d- Madison J et al 2012; e- Miyagata Y et al, 2011; f- Limdi 
NA et al, 2008; 
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Table 24. Comparison of CYP2C9, CYP2C19, CYP3A5 and VKORC1 genotypes and alleles between healthy 
male and female in Kosovo’s population  
(SPSS Inc., Chicago, IL, USA, 20.0 version; https://www.allto.co.uk/tools/statistic-calculators/confidence-interval-for-proportions-calculator/) 
Gene and 
genotypes 
(this study) 
Male Female  
n % 95% CI n % 95% CI χ 2 p value Reference 
CYP2C9 genotypes 
*1*1 57 48.3 39.28 - 57.32 60 51.7 42.61- 60.79 0.25 0.62 Present study 
*1*2 34 28.8 20.63 - 36.97 28 24.1 16.32-31.88 0.64 0.42  
*1*3 21 17.8 10.9 - 24.7 18 15.5 8.91-22.09 0.25 0.62  
*2*2 4 3.4 0.13 - 6.67 4 3.44 0.12 - 6.76 0.0 1.0  
*2*3 1 0.84 -0.81 - 2.49 3 2.6 -0.3 - 5.5 1.0 0.32  
*3*3 1 0.84 -0.81 - 2.49 3 2.6 -0.3 - 5.5 1.0 0.32  
Total n=118   n=116      
CYP2C9 alleles (n) 
*1 169 71.6 65.85-77.35 166 71.55 65.74-77.36 0.0 1.0 Present study 
*2 43 18.2 13.28-23.12 39 16.8 11.99-21.61 0.16 0.69  
*3 24 10.17 6.31%-14.03 27 11.6 7.48 - 15.72 0.25 0.62  
Total 2n=236   2n=232      
CYP2C19 genotypes 
*1*1 51 43.2 34.26-52.14 56 48.3 39.21 - 57.39 0.64 0.42 Present study 
*1*2 24 20.3 13.04-27.56 19 16.4 9.66 - 23.14 0.64 0.42  
*2*2 1 0.84 -0.81 - 2.49 4 3.44 0.12 - 6.76 1.96 0.16  
*2*17 5 4.2 0.58 - 7.82 3 2.6 -0.3 - 5.5 0.49 0.48  
*1*17 31 26.3 18.36-34.24 30 25.9 17.93 - 33.87 0.01 0.92  
*17*17 6 5.1 1.13 - 9.07 4 3.44 0.12 - 6.76 0.36 0.55  
Total  n=118   n=116      
CYP2C19 alleles (n) 
*1 157 66.52 60.5 - 72.54 161 69.39 63.46 - 75.32 0.49 0.48 Present study 
*2 31 13.13 8.82 - 17.44 30 12.93 8.61 - 17.25 0.01 0.92  
*17  48 20.33 15.2 - 25.46 41 17.67 12.76 - 22.58 0.49 0.48  
Total 2n=236   2n=232      
CYP3A5*3 
C/C 117 99.15 97.49-100.81 113 97.4 94.5-100.3 1.0 0.32 Present study 
C/T / / / / / / / /  
T/T 1 0.85 -0.81 - 2.51 3 2.6 -0.3 - 5.5 1.0 0.32  
Total n=118   n=116      
C 234 99.15 97.98- 100.32 226 97.4 95.35 - 99.45 2.25 0.13  
T 2 0.85 -0.32 - 2.02 6 2.6 0.55 - 4.65 2.25 0.13  
Total 2n=236   2n=232      
VKORC1 
C/C 36 30.5 22.19 - 38.81 42 36.2 27.45- 44.95 0.81 0.37 Present study 
C/T 63 53.4 44.4 - 62.4 58 50.0 40.9 - 59.1 0.25 0.62  
T/T 19 16.1 9.47 - 22.73 16 13.8 7.52 - 20.08 0.25 0.62  
Total n=118   n=116      
C 135 57.2 50.89 - 63.51 142 61.2 54.93- 67.47 0.81 0.37  
T 101 42.8 36.49 - 49.11 90 38.8 32.53- 45.07 0.81 0.37  
Total 2n=236   2n=232      
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5.1.1. CYP2C9 
 
This study investigated the CYP2C9 *2 and *3 variant allele. The frequencies of CYP2C9 alleles 
were as follows: CYP2C9*2=17.52% (mean frequency in Caucasians is 17%) and 
CYP2C9*3=10.89% (mean frequency in Caucasians is 10%). CYP2C9*1 is present with 71.58%. 
117 subjects (50.00%) were EM (CYP2C9*1/*1), 101 (43.15%) with the CYP2C9*1/*2 or 
CYP2C9*1/*3 genotype were classified as IM, while 16 subjects (6.81%) with the CYP2C9*2/*2, 
CYP2C9*2/*3 or CYP2C9*3/*3 genotype were PM. Result details are shown in tables 14-16. 
Statistical analysis didn't show any significant difference between male and female participants 
concerning allele or genotype frequency (Table 23).   
 
 
 
5.1.2. CYP2C19 
 
The CYP2C19 *2 and CYP2C19 *17 allele were the main target of this investigation. The *3 
variant allele of CYP2C19 was not investiagted because it was not found or was extremely rare in 
Caucasian populations. CYP2C19*1 allele frequency in healthy Kosovars was 68.16%. *2 and 
*17 allele frequency was 13.03% and 19.01% respectively. EM that are carriers of two normal 
alleles (CYP2C19*1/*1) in the present study participated with 45.72% (107 subjects), while 
heterozygous participants (CYP2C19*1/*2 and CYP2C19*2/*17) that were classified as IM 
participated with 21.78% (51 subjects). 5 subjects (2.13%) with the CYP2C19*2/*2 genotype 
were PM. 71 subjects (30.33%) with the CYP2C19*1/*17 or CYP2C19*17/*17 genotype were 
classified as UM, among them 10 subjects (4.27%) were homozygous carriers of *17 allele. 8 
subjects (3.41%) were carriers of the combined genotype CYP2C19*2/*17 (Table 17 and 18). 
For CYP2C19 alleles and genotypes was found no significant difference between male and 
female participants of present study (Table 23).   
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5.1.3. CYP3A5 
 
Considering its importance, we investigated the frequency of the CYP3A5*3 allele. The 
frequency of genotypes of CYP3A5*3 allele in this research were as follows: 230 subjects (98%) 
carried the CYP3A5*3/*3 genotype and were classified as non-expressors, 4 subjects (2%) were 
carriers of the CYP3A5*1/*1 genotype and classified as expressors, while the CYP3A5*1/*3 
genotype was not found (Table 19 and 20). CYP3A5*3‟s frequency was 98.3%. We found no 
significant difference between participants of both sexes (Table 23).   
 
 
 
5.1.4. VKORC1 
 
The focus of this investigation was the 1173C>T (or C6484T) variant of VKORC1. Given that the 
VKORC1 1173C>T variant is in linkage disequilibrium with the -1639 G > A (or G3673A) 
variant, we decided to investigate VKORC1 1173C>T alone. 78 (33,3%) subjects were 
homozygous for 1173C, 121 (51,7%) were heterozygous (CT) and 35 (14.95%) were 
homozygous for 1173T (Table 21 and 22). In our study, there was no significant difference 
between subjects of both sexes (male vs female) with regard to genotypes and alleles frequency 
(Table 23).  
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6. DISCUSSION  
 
The concept of "personalized medicine has been active in medical practice" in recent years. A 
better understanding of interindividual differences in DNA sequence has improved our ability to 
associate the effect of a medicinal product on certain gene variants, which is the subject of 
pharmacogenetics/pharmacogenomics. This has resulted in a greater emphasis of the 
pharmaceutical industry, academia, healthcare professionals and regulators on thestudy of the 
genetic basis of variability in response to pharmacotherapy. While scientific knowledge in this 
area is well documented, knowledge transfer and application in clinical practice is slow. This has 
resulted in the establishment of a network of societies the main objective of which is to issue 
recommendations and clear guidelines on how to adjust therapy according to the results of 
pharmacogenetic analysis. One of the most prominent ones is the Pharmacogenomics Knowledge 
Base association -PharmGKB (http://www.pharmgkb.org). On its website, users can find the 
latest information regarding molecular mechanisms of different pharmacogenes, as well as their 
inputs in pharmacotherapy. The database allows searches of genes and their variants, biochemical 
pathways as well as medicinal products and diseases. A consortium entitled Pharmacogenetics 
Clinical Implementation Consortium (CIPC) has been established with the purpose to collect and 
implement knowledge. The main objective of the CPIC is to issue peer-reviewed, updated, 
evidence-based and freely available instructions and guidelines for the use of medicines 
according to the results of genetic tests. Further progress in the individualization of therapy is 
directed towards the development of medicines appropriate for specific subpopulations of 
patients. There are a number of examples showing the benefits of an individualized approach to 
choosing a medicine and its dose compared to the approach based on the results of population-
level pharmacokinetic studies. Pharmacogenomics represents an important link in "personalized 
medicine" with emphasis on genomic and epigenomic factors that influence pharmacokinetics 
and pharmacodynamics and is also important in understanding drug interactions. While our 
knowledge of epigenomics as a modulator of pharmacotherapy efficiency is still in the 
developmental stage, a large amount of information about the impact of genomic factors is 
readily available. It is believed that since genetic factors account for about 25% - 50% of all the 
unexpected reactions to a medicinal product, it may negatively affect the efficacy of a medicinal 
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product and increase the risk of adverse reactions. Integrating genomic biomarkers in clinical and 
other studies, as well as information on methodologies used, must follow certain principles that 
take into account and consider the impact of biomarkers in the study and analysis of outcomes 
with the intention of maximizing the benefits for the patient. Important emphasis in association 
studies is placed on phenotypic data that need to comply with the international standardized 
criteria. 
Many investigations proved that ethnic specificities have a direct impact on pharmacogenetic 
characteristics. This study isthe first investigation which explored the distribution and frequency  
of variant alleles of enzymes that have a crucial role in biotransformation of a large number of 
xenobiotics (including drugs) in Kosovo‟s healthy population. The basic purpose was to explore 
distribution of important biomolecular markers in order to determine the risk group of individuals 
concerning the drug dosing and, consequently, drug‟s side effects.  
 
6.1. Phase I metabolism interethnic variability 
 
Human beings as other living organisms have developed different metabolic pathways to 
eliminate products of metabolism (toxins). Many metabolic enzymes characterized by different or 
partial similarities regarding catalytic properties have a key role in the process of detoxication 
and elimination of metabolic products. In the past, evolution of those genes that code the CYP 
450 superfamily of enzymes has made possible the survival of the human being in different 
habitats and usage of food that contained hazardous chemicals. It is believed that on earth, the 
ancestral CYP 450 gene has been arisen nearly 3,5 billion years ago, and over the time has 
undergone evolutionary changes that has made possible various functions for which it is known. 
In the evolutionary process of living species, including human beings, species have survived 
because they gained the ability to metabolize xenobiotics at the level that made possible their 
survival.  Nevertheless, living species, including human beings, differ significantly (Guengerich 
and al 1987; Danielson PB, 2002). Recently, it is these exact evolutionary processes (Hiratsuka 
M, 2016) that explain the documented interethnic differences in drug metabolism in humans.  
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6.1.1 Frequency and distribution of genotypes of CYP 450 enzymes and drug target 
(VKORC1) in Kosovo’s healthy population 
 
To date, the majority of European countries have reported the frequency of genetic 
polymorphisms of the above-mentioned enzymes and drug target. However, this data is missing 
in the case of Kosovo‟s population.  
In this investigation, for the first time, we determined the frequency of genetic polymorphism of 
CYP2C9, CYP2C19, CY3A5 and VKORC1 in Kosovo‟s healthy population. 
Participants of this study originated from all the parts of Kosovo representing a mixed and 
appropriate sample of Kosovars. All of them were ethnic Albanians. In most cases, the frequency 
of variant alleles and genotypes was in accordance with the data from other white Caucasian 
populations (Buzoianu AD et al 2012). 
 
6.1.1.1 CYP2C9 
 
In Kosovo's population, the frequency of CYP2C9 variant alleles is in accordance with the mean 
frequency of these alleles in Caucasians. CYP2C9*2=17.52% (mean frequency in Caucasians is 
17%) and CYP2C9*3=10.89% (mean frequency in Caucasians is 10%) (Applied Biosystems®). 
Our data correspond to the data on Croats published by Bozina et al (2003) and data on French 
people published by Yang JQ et al (2003). The frequency of poor CYP2C9 metabolizers in the 
present study was 6.8%, which is close to that of the Spanish population (5%) 
(http://www.1000genomes.org/). The prevalence of poor metabolizers (6.8%) in this study is 
almost similiar to Kosovo‟s neighbouring countries such as Macedonia (p= 0.3696), Greece (p = 
0.2123) or Croatia (p= 0.0857) but on the other side differs significantly compared to Sweden (p 
= 0.0090), United Kingdom (p=0.0345) or Russia (p= 0.0077) (Arvanitidis K et al 2007; Ramsjö 
M et al 2010; Korytina G et al 2012; Kapedanovska Nestorovska A et al 2014). 
In Caucasians, individuals that possess *2 and *3 variant of CYP2C9 have a low enzymatic 
activity compared to subjects that are carriers of two normal alleles. The most common variant 
allele of the CYP2C9 gene among Caucasians is CYP2C9*2. CYP2C9*2 and CYP2C9*3 alleles 
in Caucasians are present with 12.5-16.5% (2C9*2) and 7.1-9.5% (2C9*3) respectively (Bozina 
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et al 2003; Yang JQ et al 2003; Sánchez-Diz P et al 2009). The frequency of CYP2C9*2 in the 
Mediterranean European countries and other parts of Europe was: Spain (16%), Greece (12.9%), 
Croatia (14%), Romania (11.3%), Germany (14.0%), France (15%) and Sweden (10.7%) (Yasar 
U et al 1999; Burian M et al 2002; Dorado P et al 2003; Arvanitidis K et al 2007; Buzoianu, A. 
D. Et al 2012; Ganoci, L. et al 2017). 
The CYP2C9*2 variant is rare (prevalence: 0 - 0.1%) in Asian populations, especially in countries 
of Eastern Asia such as Japan, China and Korea. The prevalence of the CYP2C9*2 variant 
decreases in the direction from Europe toward Eastern Asia.  In Asia, CYP2C9*3 manifests the 
highest prevalence in the population of Southern Asia (11.7%) (Céspedes-Garro C et al 2015) 
while in the Balkans it is present at the following frequency: Croatia 9.5%, Greece 8.13% and 
Macedonia 7.3% (Bozina et al 2003; Azarpira, Namazi et al. 2010; Buzoianu AD et al 2012).  
The CYP2C9*2 and CYP2C9*3 variants are present at a lower frequency among Africans (3.3% 
and 2.3%) compared to Caucasians (Yang ZF et al. 2010; Kudzi W et al. 2016).  
6.1.1.1.1. Drug Dosing Guidelines 
 
1. As one of the COX-2 inhibitors, celecoxib is metabolized primarily by CYP2C9. The 
administration of celecoxib in individuals that are previously known or suspected to be poor 
metabolizers should be done with caution. For this category of individuals, one should consider 
dose reduction by 50% or alternative management for juvenile rheumatoid arthritis (On FDA 
Biomarker List).   
2. In vitro studies have shown that CYP2C9 is an important enzyme in the metabolism of 
flurbiprofen (NSAIDs). Flurbiprofen should be administered with caution in poor CYP2C9 
metabolizers because decreased clearance of this drug may generate high plasma levels (On FDA 
Biomarker List).      
3. Drug label for lesinurad (urate transporter inhibitor), which is approved by FDA, states that in 
CYP2C9 poor metabolizers exposure to the drug is increased. Therefore, in dealing with these 
individuals, it is necessary to be cautious (On FDA Biomarker List).   
4. The FDA-approved drug label for dronabinol (orally active cannabinoid) indicate that 
individuals who carry variant alleles that result in reduced CYP2C9 function may have two or 
three fold higher drug level in the blood (On FDA Biomarker List). 
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5. According to the FDA-approved drug label for piroxicam, CYP2C9 poor and intermediate 
metabolizers showed higher systemic levels of drug in comparison to normal/extensive 
metabolizers. Hence, in this category of patients (known or suspected poor CYP2C9 
metabolizers) should consider a dose reduction (On FDA Biomarker List).    
6. Anticoagulant warfarin routinely is used for prophylaxis and treatment in cases of atrial 
fibrillation, venous thrombosis, cardiac valve replacement, pulmonary embolism, 
thromboembolic complications and to reduce reinfarction. Dosing information related to 
pharmacogenomics for variants of CYP2C9 and VKORC1 is provided within the drug label.  
The warfarin label states that patients carrying deficient protein C (PROC) or protein S (PROS1) 
after warfarin administration experienced tissue necrosis (On FDA Biomarker List).       
7. The European Public Assessment Report (EPAR) of EMA (European Medicines Agency) for 
voriconazole lacks pharmacogenetic information. That report contains only warning information 
concerning co-administration of drugs that are known as substrates, activators or inhibitors of 
CYP3A4, CYP2C9 or CYP2C19 as a result of drug-drug interactions [voriconazole (VFEND) 
EMA drug label]. 
8. Pharmaceuticals and the Medical Devices Agency of Japan (PMDA) notes that patients with 
the CYP2C9*1*3 or CYP2C9*3*3 genotype after receiving celecoxib (brand name: Celecox) had 
an increased Area Under the Curve (AUC) as compared to individuals containing the 
CYP2C9*1*1 genotype (PMDA, Pharmaceuticals and Medical Devices Agency, Japan).  
9. Celecoxib (CELEBREX) monograph states that in individuals who are CYP2C9 poor 
metabolizers, administration of this drug should be done with caution. Additionally, in these 
individuals just half of the lowest recommended dose of the drug should be administered, with a 
maximum of 100mg as a daily dose.  Nevertheless, the celecoxib monograph does not discuss 
CYP2C9 genotyping prior to treatment (celecoxib product monograph).   
10. The product monograph for anticoagulant warfarin (brand name: COUMADIN) states that 
individuals that are carriers of two copies of *2 or *3 alleles of CYP2C9 may require reduced 
mean daily warfarin dose and are exposed to a greater bleeding risk, compared to those that have 
a CYP2C9*1*1 genotype. In addition, the presence of VKORC1 variant alleles such as -
1639G>A, is associated with adequate changes in the dose requirement of warfarin (Health 
Canada or Santé Canada).   
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6.1.1.2. CYP2C19 
 
With regard to CYP2C19, we found that frequencies of CYP2C19*2 and CYP2C19*17 variant 
were 13.03% and 19.01%, respectively. Study data are comparable to other Caucasians. We 
found high a similarity of CYP2C19 variant alleles and genotypes between Kosovo, on the one 
side, and Macedonia (p value for 2C19*2 and 2C19*17 variant was 0.55 and 0.69 respectively) 
and Greece (p value for *2 and *17 variant of CYP2C19 was 1.00 and 0.84 respectively), on the 
other. Our findings also showed a significant difference compared to other Caucasian such as 
Russians (p value for CYP2C19*1*1 was 0.0003), or even more difference compared to 
populations of other continents such as Colombia (South America) or India (p<0.0001) (Isaza C 
et al 2007; Ragia G et al 2009; Anichavezhi D et al 2012; Jakovski K et al 2013; Sychev DA et al 
2015).  
The CYP2C19*2 presence in Caucasian populations varies from 13.07-18.7%. The prevalence of 
CYP2C19*2 in Asians is 13.1- 42.2% (Anichavezhi D et al 2012; Payan M et al 2015) and even a 
twofold higher frequency of this allele was observed in Native populations from Oceania 
(61.30%). In some populations, both the CYP2C19 variants can have a frequency of up to 90% 
(Fricke-Galindo I et al 2016). In Africans and African Americans CYP2C19*2 frequency ranges 
from 12-15% (Scott SA et al 2011; Strom CM et al 2012). We have found 5 subjects (2,13 %) to 
be carriers of two *2 allele (CYP2C19*2/*2 genotype). As both variant alleles are defective 
(inactivating), it can be rather significant for the administration of antiplatelet drug clopidogrel, 
which needs to be activated predominantly by CYP2C19 enzyme.  
As regards the CYP2C19*17 variant, its frequency in Caucasians varies from 15.4% to 20.2% 
(Halling J et al 2005; Jakovski K et al 2013). The frequency of CYP2C19*17 in Asians and 
African Americans is 1.3-21% and 19% respectively (Sugimoto K et al 2008; Strom CM et al 2012; 
Payan M et al 2015).  The CYP2C19*17 allele frequency in Kosovo population was 19.01%, 
while 10/234 (4.27%) were carriers of CYP2C19*17/*17 genotype. The frequency of 
CYP2C19*17 carriers was 33.74%, with 107 subjects (45,72 %) being homozygous carriers of 
the CYP2C19*1/*1 genotype. This data is almost similar to the data on the Croatian, Greek and 
Macedonian populations. The CYP2C19*17 allele was documented to be more frequent in 
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Mediterranean Europeans and inhabitants of Middle East, than in populations of Eastern Asia 
(Fricke-Galindo I et al 2016).   
Even though carriers of the CYP2C19*1/*17 and CYP2C19*17/*17 genotype were predicted to 
be ultrarapid metabolizers, only homozygous carriers of the *17/*17 genotype has been reported 
to increase the rate of metabolism of CYP2C19 substrates like tricyclic antidepressants (TCAs) 
and esomeprazole (PPi) compared to extensive metabolizers (EM). Carriers of the CYP2C19*17 
allele who were under the treatment with clopidogrel, were associated with an increased risk of 
bleeding, especially those who carried the CYP2C19*17/*17 genotype (Dai ZL et al 2012) who 
had the highest risk. We have found 8 subjects (3,41 %) who were carriers of the 
CYP2C19*2/*17 combined genotype. Metabolic phenotype of individuals that are carriers of 
*2/*17 genotype is difficult to predict and actually is a matter of debate. Some data suggests that 
the presence of CYP2C19*17 allele may not compensate for CYP2C19*2 (Hicks JK et al 2016).  
Because the CYP2C19*3 variant (c.636G>A; rs4986893) was found extremely rarely in 
Caucasian populations (0-0.3%) (Gaikovitch EA et al 2003; Scordo MG et al 2004), it was not 
included in the panel tested in this study. On the contrary, the CYP2C19*3 variant is very 
frequent in Asian populations, especially in Japan, Korea and Vietnam (11-14%) (Jin T et al 
2016). Approximately, the frequency of the *3 variant among Asians is 2-9% (Scott SA et al 
2011), while in Africans this variant is very hard to find (Allabi AC et al 2003).  
6.1.1.2.1. Drug Dosing Guidelines 
 
1. Updated CPIC Dosing Guideline for tricyclic antidepressant amitriptyline recommends an 
alternative drug for poor, rapid or ultrarapid CYP2C19 metabolizers and poor or ultrarapid 
CYP2D6 metabolizers. For example, in CYP2C19 and CYP2D6, poor metabolizers should 
consider a 50% dose reduction (Hicks JK et al 2016). 
2. Considering that Tricyclic antidepressants (TCAs) have comparable pharmacokinetic 
properties, it may be reasonable to apply CPIC Dosing Guideline recommendations for 
amitriptyline and both CYP2C19 and CYP2D6 to other TCAs such as clomipramine, imipramine, 
doxepine and trimipramine (Hicks JK et al 2016).    
3. Another important instruction of CPIC Dosing Guideline is related to clopidogrel. For 
individuals that are poor or intermediate CYP2C19 metabolizers, this dosing guideline 
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recommends an alternative antiplatelet drug such as prasugrel or ticagrelor if there is no 
contraindication (Scott SA et al 2013).  
4. The CPIC Dosing Guideline for sertraline (selective serotonin reuptake inhibitor-SSRI), in 
individuals that are CYP2C19 poor metabolizers recommends selecting an alternative drug which 
is not metabolized mainly by CYP2C19 enzyme or reduction to 50% of recommended starting 
dose and titrating to response (Hicks JK et al 2015). 
5. For adult patients that are CYP2C19 poor, rapid or ultrarapid metabolizers, the CPIC dosing 
guideline for triazole antifungal voriconazole recommends choosing an alternative drug whose 
metabolism is not dependent on CYP2C19 enzyme. A similar treatment strategy should be 
applied in pediatric poor or ultra-rapid metabolizers. In pediatric patients that are known as rapid 
metabolizers, the recommended standard dosing should be initiated and thereafter therapeutic 
drug monitoring (TDM) should be conducted in order to titrate drug‟s dose to therapeutic trough 
concentrations (Moriyama B et al 2016). 
6. The CPIC Dosing Guideline for the citalopram and escitalopram (SSRI) in CYP2C19 
ultrarapid metabolizers, recommends selecting an alternative drug which is not metabolized 
primarly by CYP2C19. For poor CYP2C19 metabolizers, recommendation is to consider a 50% 
reduction of standard recommended starting dose and after that to titrate to response or to 
administer an alternative drug for whose metabolism CYP2C19 is not the major metabolic 
enzyme (Hicks JK et al 2015).  
7. For individuals who are CYP2C19 ultrarapid metabolizers, recommendation is to monitor 
escitalopram and citalopram plasma concentration and to titrate TC antidepressant‟s dose up to a 
maximum of 150% in response to efficacy and adverse drug reactions or to select an alternative 
drug (Swen JJ et al 2011).   
8. With respect to antiplatelet drug clopidogrel, the Dutch Pharmacogenetics Working Group 
Guideline (DWPG) recommends selection of an alternative drug for poor or intermediate 
CYP2C19 metabolizers because in these individuals there is an increased risk for reduced 
response to clopidogrel (Swen JJ et al 2011).  
9. Ultrarapid CYP2C19 metabolizers should be informed prior to esomeprazole administration 
for insufficient response to this drug. Hence, one should consider increasing dose of 
esomeprazole by 50-100% (Swen JJ et al 2011).   
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6.1.1.3. CYP3A5 
 
With respect to the CYP3A5*3 allele, 98.3% of participants in our study had the CYP3A5*3/*3 
genotype and were classified as non-expressors. These data corresponds to the observed 
prevalence of CYP3A5*3 in other Caucasians (Kapedanovska Nestorovska A, et al 2014; Ganoci 
L, et al 2017; Daly AK et al 2015). The prevalence of the CYP3A5*3 variant in different 
populations is as follows: in Caucasians its prevalence varies from 85% to 95.5%, in Afro-
Americans is 27.9%, in Eastern Asians (Koreans, Chinese and Japanese) is 69-76.7% while in 
Southern Asians (Indians) is approximately 59.4% (Adler G et al 2009; Ganoci L et al 2017). The 
present study was conducted in order to explore the frequency of the CYP3A5*3 allele in 
Kosovo‟s population, considering that this variant allele plays an important role in the 
pharmacokinetics of imatinib (tyrosine kinase inhibitor) which is a drug of choice in 
pharmacotherapy of blood malignancies such is CML (chronic myeloid leukemia) (Ma LM et al 
2015), as well as for tacrolimus, which is a basic therapy for immunosuppression in patients who 
underwent solid organ and hematopoietic stem cell transplantation. Statistical analysis showed 
that this variant is more frequent in Kosovars than in other Caucasian populations. 
6.1.1.3.1. Drug Dosing Guideline 
 
The CPIC dosing guideline for tacrolimus notes that in individuals who are extensive or 
intermediate CYP3A5 metabolizers, the starting dose should be 1.5 to 2 fold higher than the 
recommended starting dose.  Beside this, the total starting dose should not exceed 0.3 mg/kg/day. 
The CPIC dosing guideline for tacrolimus also recommend performing TDM to guide dose 
adjustment (Birdwell KA et al 2015).  
 6.1.1.4. VKORC1 
VKORC1 is another gene explored in this study. Exactly, we investigated 1173C>T (or C6484T) 
variant in Kosovo‟s population. 33,3% of subjects were homozygous for 1173C allele, 51,7% 
were heterozygous (CT) and 14.95% were homozygous for 1173T allele. The T allele (variant 
allele) frequency in our study was 40,81% while for the C allele was 59.19%. Genotyping of 
VKORC1 1173C>T (or -1639 G > A) and CYP2C9*3 allele may predict about 50% of the 
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interindividual variability of the acenocumarol response, providing a much safer anticoagulant 
therapy (Bodin L et al 2005). 
In other populations, frequencies of specific genotypes are as follows: for example, the TT 
genotype of VKORC1 (1173C>T) (homozygous for variant allele) in Caucasians appears in 
approximately of 38% of individuals, whereas in Asians occurs in 91-93% of the population. In 
Africans, the TT frequency is only 0.9% (Limdi NA et al, 2008; Mandic D et al, 2015; Yan X et 
al, 2015).  However, none of the studies has investigated the frequency of major allelic variations 
of VKORC1 in Kosovo. 
Frequencies of VKORC1 genotypes in this study correspond to the relevant genotypes of the 
Balkan populations such as Croats (CC=33.9%, CT=46.8% and TT=19.4%), Macedonians 
(CC=39.6%, CT=45.5% and TT=14.9%) or Romanians (CC=32.2%, CT=51.2% and TT=16.6%) 
but differ from other European countries such as Italy (CC=43.2%, CT=43.9% and TT=12.9%) 
(Mazzaccara C et al 2013; Kapedanovska Nestorovska A, et al 2014; Mandic D et al, 2015). 
Interestingly, comparing our data with that from Australia, we found no significant difference for 
both genotypes (p = 0.1164 for TT genotype) and variant alleles (p = 0.6145 for T allele 
frequency). On the other hand, comparison of the present study results with the data obtained 
from China (Asia) and African Americans showed a significant difference (p<0.0001) (Yan X et 
al, 2015; Limdi NA et al, 2008). 
6.1.1.4.1. Drug Dosing Guidelines 
 
1. The Clinical Pharmacogenetics Implementation Consortium published an updated guideline for 
pharmacogenetics-guided warfarin dosing. These recommendations for warfarin dosing are based 
on the VKORC1, CYP2C9, CYP4F2, and rs12777823 genotypes and are valid for pediatric and 
adult patients that share a continental ancestry (Johnson JA et al 2017). 
2. Although it has been found that the VKORC1 genotype is important contributor to the 
acenocoumarol dose variability, no dosing recommendations are available yet. INR should be 
checked frequently in those individuals carrying AA genotype at rs9934438 (Swen JJ et al 2011).  
3. In patients treated with oral anticoagulant phenprocoumon, checking of INR should be 
performed frequently in those carrying the AA genotype at VKORC1 rs9934438 (Swen JJ et al 
2011). 
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Table 25. Table presentation of drug labels containing pharmacogenetic (PGx) information 
approved by FDA (US Food and Drug Administration), EMA (European Medicines 
Agency), PMDA (Pharmaceuticals and Medical Devices Agency, Japan) and HCSC (Health 
Canada or Santé Canada) 
Drug  FDA EMA PMDA HCSC 
Amitriptyline Actionable PGx    
Aripiprazole Actionable PGx 
(has dosing 
information) 
Actionable PGx  Actionable PGx 
Atorvastatin Actionable PGx  Actionable PGx Actionable PGx 
Carisoprodol Actionable PGx    
Carvedilol Actionable PGx   Actionable PGx 
Celecoxib Actionable PGx 
(has dosing 
information) 
 Actionable PGx Actionable PGx 
Citalopram Actionable PGx 
(has dosing 
information) 
  Actionable PGx 
Clomipramine Actionable PGx    
Clopidogrel Actionable PGx Actionable PGx Actionable PGx Actionable PGx 
Codeine Actionable PGx  Actionable PGx Actionable PGx 
Dapsone Actionable PGx  Actionable PGx Actionable PGx 
Dextromethorphan Genetic testing 
recommended 
Actionable PGx   
Diazepam Actionable PGx    
Erythromycin Actionable PGx   Actionable PGx 
Ethinyl estradiol Informative PGx Genetic testing 
required 
 Actionable PGx 
Fluoxetine Informative PGx    
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Glibenclamide Actionable PGx   Actionable PGx 
Glimepiride Actionable PGx Actionable PGx  Actionable PGx 
Glipizide Actionable PGx    
Imatinib Genetic testing 
required 
Genetic testing 
required 
Genetic testing 
required 
Genetic testing 
required 
Imipramine Actionable PGx    
Indinavir  Informative 
PGx 
  
Irinotecan Actionable PGx 
(has dosing 
information) 
 Genetic testing 
recommended 
 
Lansoprazole Informative PGx    
Lidocaine Actionable PGx    
Nelfinavir Informative PGx Informative 
PGx 
  
Omeprazole Actionable PGx  Informative PGx Informative 
PGx 
Ondansetron Informative PGx    
Pantoprazole Actionable PGx   Genetic testing 
required 
Phenytoin Actionable PGx   Genetic testing 
required 
Pimozide Genetic testing 
required (has 
dosing 
information) 
   
Propanolol Informative PGx Informative 
PGx 
  
Quinine Actionable PGx   Actionable PGx 
Rabeprazole Actionable PGx  Actionable PGx Actionable PGx 
Ritonavir  Informative   
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PGx 
Sildenafil  Informative 
PGx 
  
Sirolimus  Informative 
PGx 
  
Tamoxifen Actionable PGx   Genetic testing 
required 
Telithromycin  Informative 
PGx 
  
Warfarin Actionable PGx 
(has dosing 
information) 
   
https://www.pharmgkb.org/view/drug-labels.do 
 
PGx Level 
Genetic testing required: The label indicate that some kind of tests such as genetic testing, 
cytogenetic studies, functional protein assays, etc., should be performed before starting to use this 
drug. This requirement is valid just for a category of patients. PharmGKB considers drug labels 
that note the variant is an indication for a particular drug, suggesting a required test. If the drug‟s 
label notes that a test "should be" conducted, this is also interpreted as a requirement. 
Genetic testing recommended: The label indicates that some kind of test such as genetic testing, 
cytogenetic studies, functional protein assays, etc., is recommended before starting the use of this 
drug. This requirement is valid just for a category of patients. PharmGKB considers drug labels 
that state the testing "should be considered" to be recommending testing. 
Actionable PGx: Genetic or other testing related to gene/protein/chromosomal variants are not 
discussed by the label, but the label does contain information regarding changes in the dose, 
efficacy or toxicity due to these variants.  The label may also state contraindication of the drug in 
a specific category of patients but does not require or recommend genetic testing, functional 
protein assays or chromosomal testing.  
Informative PGx: The label notes either a gene or protein, which has an impact in the 
metabolism or pharmacodynamics of the drug, but does not contain information suggesting that 
certain variations related to these genes or proteins leads to variable responses.  
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7. CONCLUSIONS 
 
1. This study provides a useful genetic data regarding the very important drug metabolizing 
enzymes and drug target. So far, there has not been any information on the pharmacogenetic 
profile of CYP2C9, CYP2C19, CYP3A5 and VKORC1 in Kosovo‟s population.  
In the study that was conducted in Kosovo‟s healthy population for the first time, we have found 
a significant frequency of gene polymorphism of cytochrome P450 enzymes: CYP2C9, 
CYP2C19 and CYP3A5, as well as drug target VKORC1.  
Such enzymes‟ polymorphism data might be used in dose adjustment of a number of clinically 
important drugs for preventing and minimizing adverse drug reactions, which sometimes may 
even cause death.     
These polymorphisms can be very useful biomarkers in pharmacotherapy, especially in the 
individualisation of pharmacotherapy and avoidance of drug‟s side effects. In general, this 
study‟s data corresponds to the data from other white Caucasian populations but differs 
significantly compared to the data from populations from other continents.  
2.  This study did not find a significant difference between male and female participants 
regarding CYPs or VKORC1 polymorphisms.  
3. The frequency of CYP2C9*1*1 genotype in this study differs compared to a number of 
European populations. However, on the other side, the majority of other genotypes of CYP2C9 
did not differ significantly in comparison to other white Caucasian populations. Regarding variant 
alleles *2 and *3, their frequency is in accordance with the frequency of respective variant alleles 
in other European populations.  
4. The analysis of CYP2C19 polymorphisms revealed data that is similar to that from the 
neighboring countries such as Macedonia or Greece, but differs significantly when compared to 
Asians and Africans.   
5. Within the analyzed CYP polymorphisms, the presence of CYP3A5*3 gave us some interesting 
results. Its frequency was in accordance with that of Croats and Tuscans (Italy) as well as with 
residents of Utah (USA), but is different compared to data obtained from other Caucasians. There 
is a deeper difference in comparison with populations from other world areas such as Africa or 
Asia.  
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6. The latest gene that was characterized in this study was VKORC1. This study‟s findings 
regarding the VKORC1 genotypes correspond to the data from Croats, but on the other side, we 
found difference when compared to data from Italians. No significant difference was observed 
with the data from Australia, both in the case of genotypes and variant alleles. Similar to other 
polymorphisms, there is a significant difference compared with Africans and Asians. With regard 
to variant alleles, there is no difference compared to Croats or Italians but there is a clear 
difference in comparison with Asians or Africans.  
7. Finally, with respect to allelic variants, studies (including this study) have found and proved 
evident intraethnic variability apart from the interethnic differences. Therefore, Caucasians 
cannot be evaluated as a homogeneous group concerning CYP2C9, CYP2C19, CYP3A5 and 
VKORC1 variant frequencies. 
 
 
 
 
 
 
 
 
To whom it may concern 
 
Knowing the distribution of these gene variants in Kosovo may prove very useful for the future 
research of certain complex diseases and for determining the impact of geographical and climatic 
conditions in their pathogenesis. Our data will form the basis for detecting the genetic risk factors 
related to specific diseases, including the toxic potential of numerous environmental pollutants. In 
addition, they can prove relevant to clinical pharmacokinetic studies and dosage 
recommendations for the Kosovo population. 
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8. ABSTRACT 
PhD thesis: „GENETIC POLYMORPHISM OF CYP2C19, CYP2C9 AND VKORC1 IN 
KOSOVO POPULATION’ 
Valon Krasniqi 
2017 
Background: For the first time, we determined and analyzed frequency of the most important 
variant alleles of CYP2C9, CYP2C19, CYP3A5 and VKORC1 in Kosovo‟s population.   
Methods: Determination of genetic polymorphism was conducted in 234 nonrelated Kosovars 
and genotyping was conducted by Real-Time PCR. 
Results: Allele frequencies of CYP 2C9*2 and 2C9*3 were 17,52% and 10.89% respectively. 16 
subjects (6.81%) were anticipated to be poor metabolizers. For CYP2C19, *2 and *17 variant 
frequencies were 2C19*2=13.03% and 2C19*17=19.01%. CYP2C19 poor metabolizers were 
predicted to be 2.13%, while 10 subjects (4.27%) were homozygous carriers of *17 allele and 
were predicted to be UM. For CYP3A5, prevalence of *3 variant allele in Kosovo population was 
98.29 % (non-expressors). In relation to VKORC1, 33,3% of subjects of this study were found as 
homozygous (CC), 51,7% were heterozygous CT and 14.95% were homozygous for T allele.  
 
Discussion: For CYP2C9 and CYP2C19, frequency of variant alleles is in accordance with 
respective data in Caucasians especially with data of Croats, Macedonians, Greeks and French 
people. For CYP3A5*3, its frequency was in accordance with Croats and Tuscans (Italy) but is 
different compared to data obtained from other Caucasians. Data on VKORC1 (1173C>T) 
correspond to the relevant genotypes of the Balkan populations such as Croats, but differ from 
other European countries such as Italy. 
 
Conclusion: Findings of this study showed high accordance of variant alleles, genotypes and 
predicted phenotypes of Kosovars with that of other Caucasians, specifically with South Eastern 
European populations.  
 
Key words: pharmacogenetics; polymorphism; Kosovo; genotype; phenotype; variant 
allele; cytochrome P450 (CYP450); CYP2C9; CYP2C19; CYP3A5; VKORC1. 
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9. SAŽETAK (EXPANDED ABSTRACT IN CROATIAN) 
Doktorska Disertacija: ‘GENETIČKI POLIMORFIZAM CYP2C19, CYP2C9 I VKORC1 
U KOSOVSKOJ POPULACIJI’ 
Valon Krasniqi 
2017 
Pozadina: Nema podataka o farmakogenetičkim polimorfizmima u populaciji Kosova. 
Po prvi put smo odredili i analizirali učestalost najvažnijih varijantnih alela CYP2C9, CYP2C19, 
CYP3A5 i VKORC1 u populaciji Kosova. 
Metode: Genotipizacija  je  provedena  u 234 zdrava stanovnika  Kosova u dobi od 18 do 65 
godina. Svi sudionici su uključeni u ispitivanje nakon potpisivanja informiranog pristanka.  
Istraživanje je provedeno u krvno nepovezanih osoba koje predstavljaju mješovitu populaciju iz 
svih dijelova Kosova. Rodni omjer sudionika u istraživanju bio je gotovo jednak za žene i 
muškarce (116: 118). DNA je dobivena iz uzoraka krvi s antikoagulansom EDTA, uz korištenje 
komercijalnog kita QIAGEN®  za ekstrakciju DNA. Genotipizacija je provedena metodom PCR 
u stvarnom vremenu  (engl. Real-Time PCR) komercijalnim testovima  TaqMan® SNP  za 
genotipizaciju.  
Rezultati: Učestalost alela CYP2C9 *2 i 2C9 *3 je iznosila 17,52% i 10,89%. 16 ispitanika 
(6,81%) s genotipom CYP2C9*2/*2, CYP2C9*2/*3 ili CYP2C9*3/*3 pripada fenotipu  
slabih/sporih  metabolizatora (PM). Određena je i učestalosta alela CYP2C19*2 (13,03%)  i  
2C19*17 (19,01%).  Ne temelju tih rezultata predviđa se  učestalost  CYP2C19 slabih 
metabolizatora (CYP2C19 *2/*2 ) koja je  iznosila 2,13%, dok je 71 ispitanik (30,33%) s 
genotipom CYP2C19 *1/*17 ili 2C19*17/*17 klasificiran  kao vrlobrzi metabolizator (UM). 10 
ispitanika (4,27%) su bili  homozigotni nositelji alela *17. Nadalje, 8 ispitanika (3,41%) nositelji 
su kombiniranog genotipa CYP2C19*2/*17. Za CYP3A5, prevalencija alela *3 bila je 98,29% 
(nonekspresori), dok je 1,7% ispitanika kategorizirano kao ekspresori. Zanimljivo je da genotip 
CYP3A5*1/*3 nije detektiran u ovoj studiji. S obzirom na polimorfizam VKORC1 1173C> T, 
33,3% ispitanika u ovoj studiji su bili homozigotni nositelji alela C (1173CC), 51,7% su bili  
heterozigoti (1173CT) a 14,95% homozigoti za alel T (1173TT). 
Rasprava: Učestalost varijantnih alela CYP2C9 je u skladu s prosječnom učestalosti ovih alela u 
nekim bjelačkim populacijama. Npr. naši podaci odgovaraju objavljenim podacima za hrvatsku  i 
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francusku populaciju. Učestalost sporih metabolizatora putem CYP2C9, iznosila je 6,8%, što je 
blisko rezultatima za španjolsku populaciju (5%) i podudarno je podacima  za susjedne zemlje 
Kosova kao što su Makedonija (p=0,3696), Grčka (p=0,2123) ili Hrvatska (p=0,0857), dok se 
značajno  razlikuje od vrijednosti učestalosti polimorfizama objavljenih za Švedsku (p=0,0090), 
Ujedinjeno Kraljevstvo (p=0,0345) ili Rusiju (p=0,0077). 
Učestalost varijantnih alela CYP2C19 je usporediva s podacima za populaciju Makedonije i 
Grčke. Ustanovljena je značajna podudarnost u prevalenciji  varijantnih alela i genotipova 
CYP2C19 između Kosova s jedne strane i Makedonije (za 2C19*2 (p=055), i 2C19*17 (p=0,69)  
te Grčke (za 2C19*2 (p=1), i 2C19*17 (p=0,84). Naši nalazi također pokazuju značajnu razliku u 
usporedbi s ruskom populacijom (za CYP2C19*1*1 p=0.0003). Ta razlika je još značajnija u 
usporedbi s vrijednostima za populacije drugih kontinenata kao što su kolumbijska (Južna 
Amerika) ili indijska (p < 0,0001). Učestalost CYP3A5*3, je u skladu s vrijednostima 
zabilježenima u populaciji Hrvatske, Toskane (Italija), Utaha (SAD), ali se razlikuje u usporedbi 
s podacima za neke druge bjelačke populacije. Zabilježena učestalost genotipova VKORC1 
1173C> T u ovoj studiji odgovara relevantnim genotipovima balkanskih populacija kao što je 
hrvatska (1173 CC = 33,9%, CT = 46,8% i TT = 19,4%), dok se učestalost razlikuje u odnosu na 
neke europske zemlje, npr.  Italija (1173 CC = 43,2%, CT = 43,9% i TT = 12,9%). 
Zaključci: U studiji koja je po  prvi put provedena na zdravom stanovništvu Kosova, otkrili smo 
značajnu učestalost polimorfiza gena enzima citokroma P450: CYP2C9, CYP2C19 i CYP3A5, te 
ciljne molekule VKORC1. Nije ustanovljena  značajna razlika u učestalosti  polimorfizama u 
odnosu na spol.  
Nalazi ove studije pokazali su visok stupanj sukladnosti  učestalosti varijantnih  alela, genotipova 
i predviđenih fenotipova Kosovara s onima drugih autohtonih europskih etničkih skupina, osobito 
s populacijama jugoistočne Europe. Najznačajnije su razlike zabilježene u odnosu na  podatke  za 
populacije drugih kontinenata. 
 
Ključne riječi: farmakogenetika; polimorfizam; Kosovo; genotip; fenotip; varijantni alel; 
Citokrom P450 (CYP); CYP2C9; CYP2C19; CYP3A5; VKORC1. 
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